• Help prevent and protect against ALLERGY symptoms before they start
Pirinase Allergy 0.05% Nasal Spray (fluticasone propionate). Indications: Prevention and treatment of allergic rhinitis. Legal category: P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK. Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: https://www.medicines.org.uk/emc/product/4502
Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-PIRI-25-00004
WHY YOUR PHARMACY PLAYS AN IMPORTANT ROLE FOR ALLERGY SUFFERERS
PRESCRIPTION STRENGTH HAYFEVER RELIEF
In the UK, 44% of adults and 50% of children su er from an allergy 1
fexofenadine hydrochloride
Common allergies include: hayfever, allergic asthma, bites & stings, mould, pet, dust, and food allergies.2
Not all allergies are seasonal
Allergy sales in pharmacy are worth over £89 million3
POWERFUL HAYFEVER RELIEF
Relief of symptoms associated with seasonal allergic rhinitis:
• Sneezing, a runny nose, stuffy nose, itchy nose, itchy and watery eyes, sore and scratchy throat
• Non-drowsy* hayfever relief
Tablets remain the largest sector of allergy format followed by sprays3 is the no.1 selling allergy brand in pharmacy with 23.9% share3 with a wide range to suit all allergy su erers. Pharmacy line products form 28.3% of value share in the category4
Symptoms of airborne allergens including:
• Pollen (hayfever)
• Pet hair
• Dust mite
• Mould spores
Symptomatic relief of nose and eye symptoms
Use in advance of symptom onset, before contact with allergen
• Relieves symptoms for up to 24 hours
• E ectively treats eye/ocular symptoms
• Relief of all major hayfever & airborne allergy symptoms
Symptoms of:
• Hayfever
• Skin allergies such as rash, itching & nettle rash or hives
• Pet allergies
• Mould spore allergies
• House dust mite allergies
Relief of symptoms associated with seasonal allergic rhinitis.
• Sneezing, a runny nose, stu y nose, itchy nose, itchy and watery eyes, sore and scratchy throat
• Hayfever relief non-drowsy in most people
Symptomatic control of all allergic conditions responsive to antihistamines including:
• Hayfever and other allergies e.g. pet, house dust mite and mould spore allergies
• Food allergies such as itchy skin, skin rash and hives.
• Also relieves the itchy rash of chicken pox
Help your patients breathe
Syrup: 1+ Tablets: 6+
Syrup: 2+ Tablets: 6+
PREVENT AND PROTECT HAYFEVER RELIEF
UNBEATABLE STRENGTH ALLERGY RELIEF
Intranasal corticosteroids like Pirinase are recommended as first-line therapy for moderateto severe allergic rhinitis. 6 Pirinase helps relieve symptoms of airborne allergens including:
• Pollen (hayfever)
• Pet hair
• Dust mite
• Mould spores
FAST AND EFFECTIVE ALLERGY RELIEF
Suitable for use from 1 year (syrup) and 6 years (tablets), Piriton helps relieve symptoms including:
• Hayfever and other allergies
• Food allergies such as itchy skin rash and hives
• The itchy rash of chicken pox
Pirinase Hayfever Once Daily 0.0%% Nasal Spray (fluticasone propionate). Indications: For the treatment of seasonal allergic rhinitis including hayfever. Legal Category: GSL. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: https://www.medicines.org.uk/emc/product/5116/smpc
Pirinase Allergy 0.05% Nasal Spray (fluticasone propionate). Indications: Prevention and treatment of allergic rhinitis. Legal category: P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: http://www.medicines.org.uk/emc/medicine/24352
Piriteze Hayfever & Allergy 10mg Film Coated Tablets and Piriteze Children's Hayfever & Allergy 1mg/ml Syrup (cetirizine hydrochloride). Indications: Symptomatic treatment of perennial rhinitis, seasonal allergic rhinitis and chronic idiopathic urticaria. Legal category: Tablets (6 years+) and Syrup (2 years+): GSL. Syrup (2 years+): P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: https://www.medicines.org.uk/emc/product/341/smpc, https://www.medicines.org.uk/emc/product/4132/smpc, https://www.medicines.org.uk/emc/product/13429/smpc
Indications: Relief of symptoms associated with seasonal allergic rhinitis. Legal category: GSL. Licence Holder: Chanelle Medical Unlimited Company, Dublin Road, Loughrea, Co. Galway, Ireland.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at:
Piriton Children’s Allergy Syrup and Piriton Allergy Tablets (chlorphenamine maleate). Indications: Symptomatic relief of allergic conditions including hayfever, food allergy and insect bites. Symptomatic relief of itch associated with chickenpox. Legal category: P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: http://www.medicines.org.uk/emc/medicine/16103, http://www.medicines.org.uk/emc/medicine/16105
6. Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017 Jul;47(7):856-889. Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-PIRI-25-00045 up years
References:
1. The British Allergy Foundation Trustees’ Annual Report. 2020
2. Allergies. NHS. Available at: https://www.nhs.uk/conditions/allergies/ Accessed: 15/03/24
*Refers to E45 Cream for dry skin. Always read the label
Sterile natural soothing saline sprays by NeilMed.
Contains only purified water, sodium chloride, and sodium bicarbonate; USP-graded (purity level ≥99%)
New Products!!
• Sterile
• Isotonic
• Non-burning
• Delivers a fine and gentle mist
• Use as often as needed
• Isotonic
• Non-burning
• Use as often as needed
• Hypertonic (2,7%)
• Reduces congestion and swelling better than isotonic spray
• Use as often as needed
Retail Category Management
Guidance and product information for OTC brands and categories to help support the pharmacy team.
Allergy Relief
Gastro-resistant
Pain Relief
Rehydration
Erectile Dysfunction
Skin Care Incontinence Care
See this month’s book for offers on products featured in the Retail Category Management.
Advising on
moderate to severe hay fever
Supporting customers when intranasal monotherapy has not provided relief
Around a quarter of the UK population suffer from seasonal allergic rhinitis (AR), or hay fever.1 Symptoms are generally managed through self-care strategies and over-the-counter (OTC) treatment with oral antihistamines and/or intranasal corticosteroids.2
Until now, the only alternative for customers with moderate to severe hay fever symptoms that remained uncontrolled on an OTC corticosteroid nasal spray would have been to obtain a prescription-only product. There were no combination treatments in a single product available to purchase from the pharmacy.
Dymista® Control combines the antiinflammatory action of a corticosteroid (fluticasone propionate) and the anti-allergenic effect of an antihistamine (azelastine hydrochloride) in one formulation to reduce bothersome hay fever symptoms affecting the eyes and nose.3 It offers faster and more complete control
About Dymista Control (P)
Dymista® Control indicated for the relief of symptoms of moderate to severe hay fever in adults (18+ years) if monotherapy with either intranasal antihistamine or corticosteroid is not considered sufficient. The recommended dosage is one spray into each nostril, twice a day (morning and evening). The maximum daily dose should not exceed two sprays in each nostril per day. It should be used regularly to achieve full therapeutic benefit.3
Key points about Dymista® Control:3
Unique
It is the ONLY double action nasal spray containing both a corticosteroid and an antihistamine available as a Pharmacy medicine
Fast
Gets to work in five minutes
Effective
Reduces inflammation in both nose and eye symptoms (nose symptoms comprising rhinorrhoea, nasal congestion, sneezing and nasal itching and eye symptoms comprising itching, tearing/ watering and redness of the eyes) compared to placebo, azelastine alone and fluticasone alone
Assessing your
customer’s symptoms
Typical hay fever symptoms appear within minutes of exposure to grass, tree and/ or weed pollen2 and can last for weeks, or even months.5
• Sneezing
• Bilateral nasal itching
• Nasal discharge (rhinorrhoea)
• Nasal congestion
• Accompanied by itchy, red, watery eyes
Mild symptoms are not considered troublesome and they do not have an effect on sleep, work, studies and other daily activities.2 However, symptoms are classified as moderate to severe when one or more of the following applies:2
l Disturbed sleep
l Problems at work or school
l Impairment of daily activities, sport or leisure
l Troublesome symptoms
Moderate to severe symptoms can lead to a reduced quality of life due to their adverse effects on people’s work, home and social lives.2 For young adults, this could affect performance during studies and exam periods.
Dymista® Control is a suitable option for customers suffering from moderate to severe hay fever symptoms, if monotherapy with either intranasal antihistamine or intranasal corticosteroid is
• Coughing
• Postnasal drip
• Itchy throat, mouth and ears
• Snoring / mouth breathing
• Halitosis
Alternative diagnoses
Other conditions may present with symptoms that are similar to hay fever. If any of these additional symptoms are present, you should consider an alternative diagnosis:2,6
l Fever that is not improving or worsening
l Persistent cough
l Unilateral symptoms
l Coloured nasal discharge
l Blood-stained nasal discharge
l Recurrent nose bleeds
l Nasal pain
l Loss of sense of smell
l Visual disturbances
These symptoms may indicate: other types of rhinitis; sinusitis; asthma; tuberculosis; nasal structural abnormalities; a blockage, such as polyps or the presence of a foreign body; a cardiovascular condition; obstructive sleep apnoea syndrome, or a chest infection. Dymista® Control is not suitable for any of these conditions and alternative therapies or referral to a GP should be considered.6
Considerations before
supplying Dymista®Control
l Dymista® Control is contraindicated in those with a hypersensitivity to any active ingredients or excipients3
l The following customers should be referred to their GP for assessment before using Dymista® Control:3
• Pregnant, suspected pregnancy or planning to have a baby
• Breastfeeding
• Severe liver disease
• Tuberculosis or any type of untreated infection
• Fever or infection in the nasal passages or sinuses
• Recent injury or surgery to the nose or mouth or problems with ulceration in the nose
• A history of increased ocular pressure, glaucoma and/or cataracts
• Those transferring from a systemic corticosteroid
• Those who have been using intranasal corticosteroids at high doses and/or for prolonged periods (3 months or more). They may be at greater risk of systemic effects, and more rarely, a range of psychological or behavioural effects. Customers experiencing any systemic effects must be referred to their GP
• Changes in vision (e.g. blurred vision or other visual disturbances) after using systemic or topical corticosteroids.
l Customers taking the following medicines should be referred to their GP before using Dymista® Control because they interact:3
• Other corticosteroid products, such as tablets, creams, ointments, asthma medications or similar intranasal sprays or eye/nose drops
• Medicines for HIV (ritonavir or cobicistat)
• Ketoconazole.
l Those taking sedatives/central nervous system (CNS) medicines (e.g. opioids, barbiturates, benzodiazepines, anxiolytics, sleep medications, hypnotics) should be warned of the potential increase in their sedative effect when used with Dymista® Control.3
Further advice when supplying Dymista
l Common or very common side effects include epistaxis (nosebleeds), headache, unpleasant smell and unpleasant taste3
l Correct application is important and will also help to avoid the unpleasant taste. Your customer should close one nostril with a finger and place the spray pump tip just into the other nostril; tilt their head forward slightly, open their mouth and take care not to spray directly onto the nasal septum (the wall between the nostrils); keep the bottle upright and mouth open while pumping once gently and breathing in lightly through the treated nostril.3
KEEP HEAD TILTED FORWARD
*Dymista® Control has minor influence on the ability to drive and use machines3
l Your customer may have combined their previous corticosteroid nasal spray with an OTC oral antihistamine. Dymista® Control combines an intranasal corticosteroid and intranasal antihistamine, therefore they should discontinue their other oral and intranasal hay fever medication
l When using Dymista Control, customers should seek medical advice in case of:
• A severe allergic reaction (very rare)
• Blurred vision or other visual disturbances
• Discomfort due to irritation or swelling inside the nose.
Key information about
treatment duration
Your customer’s symptoms should be assessed within seven days of starting Dymista® Control. If their symptoms are not well controlled, they may not have hay fever:3
l If Dymista® Control does not lead to an improvement in symptoms within seven days, your customer should stop treatment or seek advice from their GP
l If, within seven days, symptoms have improved but are not adequately controlled, they should also seek advice from their GP or return to the pharmacy.
Dymista® Control should not be used for more than three months continuously without consulting a GP.
References:
1. Natasha Allergy Research Foundation. Allergies - The facts. 2025. https://www.narf.org.uk/the-allergy-explosion
2. NICE. CKS. Allergic rhinitis. 2024. Available at: https://cks.nice.org.uk/topics/allergic-rhinitis/
Control
To complete your learning, please refer to the following materials:
3. Dymista Control 137 microgram, 50 microgram nasal spray. SmPC. 2025. Available at: https://www.medicines.org.uk/emc/product/100435/smpc
4.Meltzer E, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161:369–377.
5. NHS. Hay fever. 2024. Available at: https://www.nhs.uk/conditions/hay-fever/
6. Dymista Control 137 microgram, 50 microgram nasal spray. Pharmacy Essential Guide. 2025. Available at: https://www.medicines.org.uk/emc/product/100435/rmms.
7. Dymista Control 137 microgram, 50 microgram nasal spray. PIL. 2024. Available at: https://www.medicines.org.uk/emc/files/pil.100435.pdf Online sources last accessed February 2025.
Product information and adverse event reporting
Please refer to the Summary of product characteristics (SmPC) for full information before recommending this product.
Dymista® Control 137 micrograms / 50 micrograms per Actuation Nasal Spray. Contains azelastine hydrochloride and fluticasone propionate. Indication: Relief of symptoms of moderate to severe seasonal allergic rhinitis in adults if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. Dosage and method of use: 18 years of age or over: The recommended dose is one actuation in each nostril twice daily (morning and evening). The maximum daily dose should not exceed 2 sprays in each nostril per day. Dymista® Control Nasal Spray should not be used in children and adolescents under 18 years of age. Dymista® Control Nasal Spray is for nasal use only. Contra-indications: Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions: Treatment should be stopped, or the advice of a doctor sought if an improvement is not seen within 7 days. The advice of a doctor or pharmacist should also be sought if symptoms have improved but are not adequately controlled within 7 days. This medicine should not be used for more than 3 months continuously without consulting a doctor. Medical advice should be sought before using this medicine in the case of: •concomitant use of other corticosteroid products, such as tablets, creams, ointments, asthma medications, similar nasal sprays, or eye/nose drops. •fever or an infection in the nasal passages or sinuses. • recent injury or surgery to the nose, or problems with ulceration in the nose. Clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing’s syndrome and adrenal suppression. Therefore, concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects. Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression, or aggression. Dymista® Control Nasal Spray undergoes extensive first-pass metabolism, therefore the systemic exposure of intranasal fluticasone propionate in patients with severe liver disease is likely to be increased. This may result in a higher frequency of systemic adverse events. Caution is advised in these patients. Treatment with higher than recommended doses of nasal corticosteroids may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. In general, the dose of intranasal fluticasone formulations should be reduced to the lowest dose at which effective control of the symptoms of rhinitis is maintained. Higher doses than the recommended one have not been tested for Dymista® Control. As with all intranasal corticosteroids, the total systemic burden of corticosteroids should be considered whenever other forms of corticosteroid treatment are prescribed concurrently. Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids. Close monitoring is warranted in patients with a change in vision or with a history of increased ocular pressure, glaucoma and/or cataracts. If there is any reason to believe that adrenal function is impaired, care must be taken when transferring patients from systemic steroid treatment to Dymista® Control Nasal Spray. In patients who have tuberculosis, any type of untreated infection, or have had a recent surgical operation or injury to the nose or mouth, the possible benefits of the treatment with Dymista® Control Nasal Spray should be weighed against possible risk. Infections of the nasal airways should be treated with antibacterial or antimycotical therapy, but do not constitute a specific contraindication to treatment with Dymista® Control Nasal Spray. Dymista® Control Nasal Spray contains benzalkonium chloride. Long term use may cause oedema of the nasal mucosa. Side-effects: Very Common (≥1/10): Epistaxis. Common (≥1/100 and <1/10): Headache, dysgeusia (unpleasant taste), unpleasant smell. Uncommon (≥1/1,000 and <1/100): Nasal discomfort (including nasal irritation, stinging, itching), sneezing, nasal dryness, cough, dry throat, throat irritation. Rare (≥1/10,000 and <1/1000): Dry mouth. Very rare (<1/10,000): Hypersensitivity including anaphylactic reactions, angioedema (oedema of the face or tongue and skin rash), bronchospasm, dizziness, somnolence, glaucoma, increased intraocular pressure, cataract, nasal septal perforation, mucosal erosion, nausea, rash, pruritus, urticaria, fatigue, weakness. Side effects where the frequency cannot be estimated from available data: blurred vision, nasal ulcers. Systemic effects of some nasal corticosteroids may occur, particularly when administered at high doses for prolonged periods. In rare cases osteoporosis was observed if nasal glucocorticoids were administered long-term. Product licence number: PL 46302/0094 Name and address of the product licence holder: Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom. Supply classification: P. Cost: £13.72 (Trade price) Document number: UK-DTC-2024-00044. Date last revised: December 2024
Please continue to report suspected adverse drug reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA. Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems(EMIS/SystmOne/ Vision/MiDatabank) or by calling the Commission on Human Medicines(CHM) free phone line: 0800-731-6789. Adverse reactions/events should also be reported to MAH at e-mail address: pv.uk@viatris.com
PRODUCT INFORMATION
Pirinase Hayfever Once Daily 0.0%% Nasal Spray (fluticasone propionate). Indications: For the treatment of seasonal allergic rhinitis including hayfever. Legal Category: GSL. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: https://www.medicines.org.uk/emc/product/5116/smpc
Pirinase Allergy 0.05% Nasal Spray (fluticasone propionate). Indications: Prevention and treatment of allergic rhinitis. Legal category: P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: http://www.medicines.org.uk/emc/medicine/24352
Piriteze Hayfever & Allergy 10mg Film Coated Tablets and Piriteze Children's Hayfever & Allergy 1mg/ml Syrup (cetirizine hydrochloride). Indications: Symptomatic treatment of perennial rhinitis, seasonal allergic rhinitis and chronic idiopathic urticaria. Legal category: Tablets (6 years+) and Syrup (2 years+): GSL. Syrup (2 years+): P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: https://www.medicines.org.uk/emc/product/341/smpc, https://www.medicines.org.uk/emc/product/4132/smpc, https://www.medicines.org.uk/emc/product/13429/smpc
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at:
Piriton Children’s Allergy Syrup and Piriton Allergy Tablets (chlorphenamine maleate). Indications: Symptomatic relief of allergic conditions including hayfever, food allergy and insect bites. Symptomatic relief of itch associated with chickenpox. Legal category: P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK.
Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: http://www.medicines.org.uk/emc/medicine/16103, http://www.medicines.org.uk/emc/medicine/16105
References:
1. The British Allergy Foundation Trustees’ Annual Report. 2020
2. Allergies. NHS. Available at: https://www.nhs.uk/conditions/allergies/ Accessed: 15/03/24
Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-PIRI-25-00068
WHY YOUR PHARMACY PLAYS AN IMPORTANT ROLE FOR ALLERGY
SUFFERERS
In the UK, 44% of adults and 50% of children su er from an allergy 1
Common allergies include: hayfever, allergic asthma, bites & stings, mould, pet, dust, and food allergies.2 Not all allergies are seasonal
Allergy sales in pharmacy are worth over £89 million3
Pharmacy line products form 28.3% of value share in the category4
Tablets remain the largest sector of allergy format followed by sprays3 is the no.1 selling allergy brand in pharmacy with 23.9% share3 with a wide range to suit all allergy su erers.
Pirinase Allergy
Symptoms of airborne allergens including:
• Pollen (hayfever)
• Pet hair
• Dust mite
• Mould spores
Symptomatic relief of nose and eye symptoms
Use in advance of symptom onset, before contact with allergen
• Relieves symptoms for up to 24 hours
• E ectively treats eye/ocular symptoms
• Relief of all major hayfever & airborne allergy symptoms
Symptoms of:
• Hayfever
• Skin allergies such as rash, itching & nettle rash or hives
• Pet allergies
• Mould spore allergies
• House dust mite allergies
Relief of symptoms associated with seasonal allergic rhinitis.
• Sneezing, a runny nose, stu y nose, itchy nose, itchy and watery eyes, sore and scratchy throat
• Hayfever relief non-drowsy in most people
Symptomatic control of all allergic conditions responsive to antihistamines including:
• Hayfever and other allergies e.g. pet, house dust mite and mould spore allergies
• Food allergies such as itchy skin, skin rash and hives.
• Also relieves the itchy rash of chicken pox
patients
Syrup: 1+ Tablets: 6+
Syrup: 2+ Tablets: 6+
PRESCRIPTION STRENGTH HAYFEVER RELIEF
fexofenadine hydrochloride
POWERFUL HAYFEVER RELIEF
Relief of symptoms associated with seasonal allergic rhinitis:
*in most people
12+ years
• Sneezing, a runny nose, stuffy nose, itchy nose, itchy and watery eyes, sore and scratchy throat
• Non-drowsy* hayfever relief tablet
Award winning eye care since 1897
Hayfever Relief Eye Drops
A straightforward, rapid and effective solution for reducing eye discomfort caused by hayfever symptoms:
Hay fe v er Re li ef 2 % w/v Ey e D ro ps So di um
Cromog li cate
Relieves and treats itchy, sore and watery eyes associated with hayfever
Pre s cr ip ti on s trength y et availabl e i n th e he al thc a re aisl e for sel f sel ect ion
Allergy eye care was the best performing category in 2023, with retail sales increasing by 17% (Euromonitor, January 2024)
Irritation & Redness Relief Eye Drops
Pharmacy only product
Rapid and prolonged relief for sore, irritated and bloodshot red eyes
Soothes Eyes so you can face the day without red and irritated eyes
Clears minor eye irritation and redness
Advanced
Murine Advanced Dry Eye Relief Eye Drops with dual action formula for fast relief and protection for frequent dry eyes
With added Aloe Vera
Suitable for all types of contact lenses
Bright & Moist Eye Drops
Murine Bright & Moist hydrates, soothes and whitens dry and sensitive eyes
Triple Action Formula with Natural Eye Whitener
Suitable for all types of contact lenses
Murine Refresh & Soothe Eye Mist for dry and tired eyes to soothe and hydrate dry and irritated eyes
With added Aloe Vera
Suitable for all types of contact lenses
Dry & Tired Eye Drops
Murine Dry & Tired hydrates, refreshes and soothes dry or tired eyes
Triple Action Formula with Witch Hazel and Gingko biloba
Suitable for all types of contact lenses
SUPPORTED WITH OVER £2M MEDIA AND IN STORE INVESTMENT
Provides soothing relief for troublesome teething when nonmedicinal treatments have not provided necessary relief
Suitable for short-term use, up to seven days in infants from the age of five months
Sugar-Free
*To verify, contact medinfo@alliancepharma.co.uk
How to recommend the right ANBESOL® product
Is your patient a teething baby?
Is the baby 5 months or older?
Anbesol products are not suitable for babies under 5 months
Lidocaine teething products such as Anbesol should be recommended as a secondline treatment after nonpharmacological teeting pain relief efforts have not been effective.
Has the patient already tried nonpharmacological treatment such as teething rings?
Is your patient suffering from recurrent mouth ulcers?
Would they prefer topical pain relief in liquid format?
Is your patient suffering from denture irritation?
Would they prefer a topical gel format with the highest strength of lidocaine available OTC for oral pain relief
Is the patient 5 months or older?
Anbesol Liquid is not suitable for babies under 5 months.
Anbesol Teething Gel or Anbesol Liquid is suitable for you to recommend for your patient when nonpharmacological treatments have been ineffective.
Anbesol Teething Gel (P) is a double action gel and the only 1% Lidocaine Hydrochloride product licensed for teething pain (from 5 months**).
**Data on file, for verification, contact medinfo@alliancepharma.co.uk
Anbesol Liquid is suitable for you to recommend to your patient.
Anbesol Adult Gel is not suitable for anyone under 12 years. If patient is 5 months+ consider Anbesol Liquid.
Is the patient 12 years or older?
Anbesol Adult Gel is suitable for you to recommend to your patient.
Anbesol Liquid (P) contains 0.9% lidocaine hydrochloride and is the only liquid format available in pharmacy for oral pain relief**. It is indicated for use in both babies (5 months +) and adults.
Anbesol Adult Strength Gel (GSL) contains 2% Lidocaine Hydrochloride, the highest strength available OTC for oral pain relief** and can be ranged as a GSL.
PRODUCT INFORMATION
Anbesol Adult Strength Gel (lidocaine hydrochloride 2.0% w/w, chlorocresol 0.1% w/w, cetylpyridnium chloride 0.02% w/w) Indication For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation. Dosage and administration Adults, the elderly and children over 12 years: apply a small amount to the affected area with a clean fingertip. One application should be sufficient. It should not be used more frequently than every 3 hours. Contraindications: Hypersensitivity to the active substances, anaesthetics of the amide-type or to any of the excipients. Unsuitable for patients with porphyria. Precautions: Not suitable for teething in children. Excessive dosage, or short intervals between doses, may result in high plasma levels and serious adverse effects (see Section 4.9). Anbesol should be used with caution in patients with wounds or traumatised mucosa in the region of the proposed application. A damaged mucosa will permit increased systemic absorption resulting in systemic effects, such as convulsions, particularly if excessive quantities are used. This medicinal product contains chlorocresol and the azo dye Ponceau 4R (E124) which may cause allergic reactions in sensitive individuals. This medicinal product contains 66.605% w/w ethanol (alcohol) (equivalent to 63.9% w/w ethanol 100%) . The small amount of alcohol in this medicine will not have any noticeable effects. Undesirable effects: Allergic reactions, non-specific ulceration, dermatitis Legal Category GSL Trade price: £2.13 (10g tube) Marketing Authorisation Number: PL 16853/0127 Marketing Authorisation Holder: Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, UK Date of revision: May 2024
Anbesol Liquid (lidocaine hydrochloride 0.9% w/w, chlorocresol 0.1% w/w, cetylpyridnium chloride 0.02% w/w. Indication Adults, the elderly and children (from 5 months of age): For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation. In children from 5 months: For relief of pain and discomfort associated with teething where nonpharmacological treatments have failed to provide sufficient relief. Dosage and administration Adults and the elderly: Apply a small undiluted amount to the affected area with the fingertip. Two applications immediately will normally be sufficient to obtain pain relief. The application may be repeated if necessary after 3 hours. Babies teething and children (from 5 months of age): One application of 0.25ml undiluted liquid. Application may be repeated if necessary after 3 hours, up to a maximum of 6 applications in 24 hours. Treatment should be stopped once symptoms have resolved. Not to be used for more than 7 days. Contraindications: Hypersensitivity to the active substances, anaesthetics of the amide-type or to any of the excipients. Unsuitable for patients with porphyria. Precautions: Do not use more than one product containing lidocaine at the same time. Excessive dosage, or short intervals between doses, may result in high plasma levels and serious adverse effects (see Section 4.9). Anbesol should be used with caution in patients with wounds or traumatised mucosa in the region of the proposed application. A damaged mucosa will permit increased systemic absorption resulting in systemic effects, such as convulsions, particularly if excessive quantities are used. This medicinal product contains chlorocresol and the azo dyes amaranth (E123) and sunset yellow (E110), which may cause allergic reactions. A dose of 0.25 ml of this medicine administered to a child 5 months of age weighing 5 kg would result in exposure to 30.2 mg/kg of ethanol which may cause a rise in blood alcohol concentration (BAC) of about 5 mg/100ml. For comparison, for an adult drinking a glass of wine or 500 ml of beer, the BAC is likely to be about 50 mg/100 ml. Co-administration with medicines containing e.g. propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects, in particular in young children with low or immature metabolic capacity. Undesirable effects: Allergic reactions, non-specific ulceration, dermatitis Legal Category P Trade price £3.49 (10ml bottle) Marketing Authorisation Number: PL 16853/0128 Marketing Authorisation Holder: Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, UK Date of revision: May 2024
Anbesol Teething Gel (lidocaine hydrochloride 1.0% w/w, chlorocresol 0.1% w/w, cetylpyridnium chloride 0.02% w/w). Indication Adults, the elderly and children (from 5 months of age): For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation. In children from 5 months: For relief of pain and discomfort associated with teething where non-pharmacological treatments have failed to provide sufficient relief. Dosage and administration Adults and the elderly: Apply a small amount to the affected area with a clean fingertip. Two applications immediately will normally be sufficient to obtain pain relief. It should not be used more frequently than every 3 hours. Babies teething and children (from 5 months): Apply a pea-sized amount (0.2 grams) of Anbesol teething gel with a clean finger to the affected area. The dose may be repeated, if necessary, after 3 hours, up to a maximum of 6 doses in 24 hours. Treatment should be stopped once symptoms have resolved. Not to be used for more than 7 days. Contraindications: Hypersensitivity to the active substances, anaesthetics of the amide-type or to any of the excipients. Unsuitable for patients with porphyria. Precautions: Do not use more than one product containing lidocaine at the same time. Excessive dosage, or short intervals between doses, may result in high plasma levels and serious adverse effects (see Section 4.9). Anbesol should be used with caution in patients with wounds or traumatised mucosa in the region of the proposed application. A damaged mucosa will permit increased systemic absorption resulting in systemic effects, such as convulsions, particularly if excessive quantities are used. This medicinal product contains chlorocresol and the azo dye Ponceau 4R (E124) which may cause allergic reactions in sensitive individuals. A dose of 0.2g of this medicine administered to a child 5 months of age weighing 5kg would result in exposure to 25.6 mg/kg of ethanol which may cause a rise in blood alcohol concentration (BAC) of about 4.3 mg/100ml. For comparison, for an adult drinking a glass of wine or 500 ml of beer, the BAC is likely to be about 50 mg/100 ml. Co-administration with medicines containing e.g. propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects, in particular in young children with low or immature metabolic capacity. Undesirable effects: Allergic reactions, non-specific ulceration, dermatitis Legal Category P Trade price £1.90 (10g tube) Marketing Authorisation Number: PL 16853/0126 Marketing Authorisation Holder: Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, UK Date of revision: May 2024
experience symptoms
Hydration, upgraded. By the time you feel thirsty, dehydration is already slowing you down, —Phizz hydrates you 3x faster than water alone, keeping your energy high and focus sharp.
Essential electrolytes, every day.
More than just for athletes, electrolytes power everything from memory to immunity. Phizz delivers seven key electrolytes to support your daily well-being.
Better water, better you.
Phizz is a science-backed shortcut to faster hydration and enhanced performance— so you can stay at the top of your game, all day.
Water’s good. Phizz makes it better.
QUICK GUIDE TO ADVISING ON
Feel confident incorporating the latest treatment for erectile dysfunction (ED) into your consultations
AVARANTE® (tadalafil 10mg) is a new* product licensed to treat ED.
AVARANTE joins VIAGRA CONNECT to expand the Viatris range of pharmacyonly medicines licensed for ED in adult men (aged 18 years and over).1,2
*New from the makers of VIAGRA CONNECT
This training is not intended to replace the AVARANTE Risk Minimisation Materials (RMMs). You can access all the RMMs via the link provided on page 3.
Tadalafil and sildenafil belong to the same drug class, namely phosphodiesterase type 5 (PDE5) inhibitors.1,2 Oral PDE5 inhibitors are regarded as the first-line drug treatment for ED in men who don’t have specific contraindications to their use.3,4
There are no significant differences in the efficacy, safety or tolerability of different PDE5 inhibitors.4 However, slight variations do exist and therefore, in specific circumstances, one product could be considered a more suitable choice than the other.
CONSIDERATIONS WHEN CHOOSING TREATMENT
The choice of PDE5 inhibitor mostly depends on the frequency of intercourse and the customer’s preference.5
The table below gives a pharmacokinetic comparison of tadalafil1 and sildenafil,2 that may be useful in your decision-making process.
Recommended time taken before sexual activity
Time to reach maximum plasma concentration
Time to onset of effect
Duration of action
to 36 hours Up to 4 hours
Rate of absorption reduced by mean of 60 minutes when taken with food, especially a
Tadalafil Sildenafil
Tadalafil
Sildenafil
Other specific considerations may include:
l Onset of action
VIAGRA CONNECT can start to work in as little as 25 minutes.2 AVARANTE can lead to erections for successful intercourse in 30 minutes.1 Customers who favour fast onset of action may benefit from using VIAGRA CONNECT as no pill works faster for ED.2
l Duration of action
VIAGRA CONNECT is effective up to 4 hours after administration.2 AVARANTE can work for up to 36 hours after taking it.1 Customers may benefit from AVARANTE’s longer window of opportunity on special occasions, such as a romantic getaway.
l Frequency of use
AVARANTE is not recommended for continuous daily use. Those who use it frequently (i.e. at least twice weekly) should discuss with their GP whether a low daily dose of tadalafil on prescription would be more suitable.1 VIAGRA CONNECT is suitable for daily use, if required.2
l Food intake
Tadalafil’s rate of absorption is not affected by food, whereas sildenafil’s rate of absorption may be reduced/delayed by a mean of 60 minutes when taken with food, especially a high-fat meal.2
l Efficacy
Most men will achieve an erection the first or second time they use a PDE5 inhibitor. However, they should be advised that it may need to be taken a number of times on different occasions before they can achieve an erection satisfactory for sexual activity. In the case of tadalafil, this should be no more than one tablet per day and no more than twice a week.1 Two metaanalyses suggest that customers who prioritise high efficacy should use sildenafil 50mg (e.g. VIAGRA CONNECT).5
l Tolerability and side effects
PDE5 inhibitors are generally well tolerated. The side effect profiles are slightly different. Tadalafil has been associated with a lower occurrence of flushing6 and visual symptoms7 compared with sildenafil,2 but possibly a higher incidence of back and muscle pain.1,2,3,6
Customers who are concerned about specific side effects may wish to bear this in mind. Two meta-analyses demonstrate that customers who are concerned about side effects should start with tadalafil 10mg (e.g. AVARANTE).5
SUPPLYING AVARANTE
ED may be referred to as erection problems (EPs) by your customers. Always ensure that you are clear on what they mean, regardless of the terminology they use, before supplying a product.
There are set criteria that must be met before an initial supply of AVARANTE can be made. The pharmacy checklist contains specific questions to check your customer’s suitability in relation to their:8
l Cardiovascular health
l Medication and recreational drug use
l Other health conditions.
When a customer requests a repeat supply, you should determine whether AVARANTE remains suitable for them by checking that:8,9
l They have not experienced any problems relating to AVARANTE
l There are no changes in their health conditions or other medications since the last supply.
Refer to the Pharmacy Guide for AVARANTE 10mg film-coated tablets (tadalafil) and AVARANTE (tadalafil) Pharmacist Checklist Quick Guide for full details. If it is not appropriate to supply AVARANTE, refer the customer to their GP. When supply is deemed appropriate, discuss the key points below with your customer.
Key advice:1,8,9
l The recommended dose is one 10mg tablet taken with or without food, at least 30 minutes prior to anticipated sexual activity
l The maximum dosing frequency is once per day; AVARANTE is not recommended for continuous daily use. Men who use this product frequently (i.e. at least twice a week) should be referred to their GP to discuss the suitability of a once-daily regimen with a lower dose, or consider an alternative treatment option
l Sexual stimulation is required for AVARANTE to work and its effects can last for up to 36 hours
l Do not take AVARANTE with grapefruit juice (this may increase the plasma levels of tadalafil)
l Do not take AVARANTE after excessive alcohol consumption
l AVARANTE works for most men on the first or second attempt, but if it does not work after several attempts, or if their ED worsens, they should be referred to their GP
l Must avoid nitrates, nitric oxide donors, amyl nitrite and nitrous oxide
l Common side effects include headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion and dyspepsia
l Seek medical attention immediately if serious side effects occur
l Advise men to inform their doctor that they have started taking AVARANTE, especially if they are prescribed any new medication.
Please refer to the SmPC and Pharmacy Guide for AVARANTE 10mg film-coated tablets (tadalafil) for full details relating to contraindications, special warnings and precautions for use, interactions and side effects. Always advise your customer to read the Patient Information Leaflet and remember to refer anyone asking for treatment for EPs to their GP for a clinical review within six months,1 regardless of whether OTC treatment has been supplied or not. Appropriate lifestyle advice should also be offered.8,9
Customer choice
The concomitant use of AVARANTE and other treatment for ED, including PDE5 inhibitors, is not recommended. A customer may switch from one oral PDE5 inhibitor to another, or from a prescription-only product to an OTC option.
Always ensure that they continue to meet the relevant criteria before supplying AVARANTE8 or VIAGRA CONNECT.10 Advise them to read the relevant Patient Information Leaflet and encourage them to inform their doctor that they are obtaining treatment for their EPs from the pharmacy.
l Customers switching from a prescription of tadalafil 10mg to AVARANTE should wait at least 36 hours after their last prescription dose before starting AVARANTE.9
l Customers switching from sildenafil 50mg on prescription, or from an OTC sildenafil 50mg product, should be advised to follow the correct dosing instructions.9
There may be instances when a customer could benefit from temporarily switching from one product to the other. For example, a customer using VIAGRA CONNECT as their usual go-to treatment may switch to AVARANTE when they plan a romantic weekend away.
NOTE: they should never be taken together at the same time, or on the same day.
The customer will need to wait at least 36 hours after their last AVARANTE dose before taking VIAGRA CONNECT on the next occasion. Customers taking VIAGRA CONNECT should wait 24 hours after their last dose before taking AVARANTE.
To find out more about AVARANTE and complete your training, visit https://www.medicines.org.uk/emc/product/100210/rmms#about-medicine
References:
1. AVARANTE 10mg film-coated tablets. SmPC. 2024. Available at: https://www.medicines.org.uk/emc/product/100210/smpc/print. 2. Viagra Connect 50 mg film-coated tablets. SmPC. 2024. Available at: https://www.medicines.org.uk/emc/product/8725 3. BNF. Erectile dysfunction. 2024. Available at: https:// bnf.nice.org.uk/treatment-summaries/erectile-dysfunction/ 4. Hatzimouratidis K, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016; 13(4):465-488. 5. Salonia A, et al. EAU Guidelines on sexual and reproductive health. 2024. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-ReproductiveHealth-2024 2024-05-23-101205 nmbi.pdf 6. Gong B, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta analysis. Int Urol Nephrol. 2017; 49:1731–1740. 7. Ahmed NS. Tadalafil: 15 years’ journey in male erectile dysfunction and beyond. Drug Dev Res. 2019; 80:683–701. 8. AVARANTE 10mg film-coated tablets (tadalafil) Pharmacist Checklist Quick Guide. 2024. Available at: https://www.medicines.org.uk/ emc/rmm/101578/Document. 9. Pharmacy Guide for AVARANTE 10mg film coated tablets (tadalafil). 2024. Available at: https://www.medicines.org.uk/emc/ rmm/101574/Document. 10. Essential information for the supply of VIAGRA CONNECT 50 mg film-coated tablets (sildenafil). 2023. Available at: https://www. medicines.org.uk/emc/rmm/1784/Document Online references last accessed December 2024
Avarante 10mg tablets Product Information
Presentation: Avarante 10mg tablets. Contains tadalafil Indication: Erectile dysfunction in adult men. Dose and Administration: Men (including the elderly) 18 years of age or over: The recommended dose is one 10mg tablet taken at least 30 minutes prior to anticipated sexual activity. The maximum dosing frequency is once per day. Avarante is not recommended for continuous daily use. Contraindications: Hypersensitivity to the active substance or to any of the excipients, co-administration with nitric oxide donors or nitrates, cardiac disease in patients where sexual activity is inadvisable, myocardial infarction within the last 90 days, unstable angina or angina during sexual intercourse, heart failure within 6 months, uncontrolled arrhythmia, hypotension (<90/50 mm Hg), uncontrolled hypertension, stroke within 6 months, non-arteritic anterior ischaemic optic neuropathy causing loss of vision in one eye, co-administration with guanylate cyclase simulators (e.g. riociguat), deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), women, those without erectile dysfunction and men under 18 years of age. Warnings and Precautions: All men with erectile dysfunction should be advised to consult their doctor within 6 months for a clinical review of potential underlying conditions and risk factors associated with erectile dysfunction. If symptoms of erectile dysfunction have not improved after taking Avarante on several consecutive occasions or if their erectile dysfunction worsens patients should consult their doctor. Patients who experience erections lasting longer than 4 hours should seek immediate medical assistance. Patients should consult their doctor before taking Avarante if they have: undergone pelvic surgery or radical non-nerve sparing prostatectomy, known hereditary degenerative retinal disorders (e.g. retinitis pigmentosa), had coronary artery bypass surgery or angioplasty, asymptomatic controlled hypertension, mild valvular disease, severe renal impairment, severe hepatic insufficiency, previous diagnosis of uncontrolled hypertension, moderate to severe valvular disease, left ventricular dysfunction, hypertrophic obstructive cardiomyopathies or significant arrhythmia, increased susceptibility to vasodilators including those with left ventricular outflow obstructions (e.g. aortic stenosis) or those with the rare syndrome of multiple atrophy, sickle cell anaemia, multiple myeloma or leukaemia. Patients with cardiovascular disease should be advised that sexual activity carries a cardiac risk and if they experience chest pain during sexual activity they should refrain from any further sexual activity and seek medical attention immediately. Avarante is not recommended for patients who experience chest pain or breathlessness after light or moderate activity. Avarante contains lactose; patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Avarante. Avarante is not recommended to be taken concurrently with recreational drugs. Interactions: Nitrates, nitric oxide donors (nicorandil, molsidomine), doxazosin and other alpha 1 adrenergic blockers, antihypertensives, riociguat, 5-alpha reductase inhibitors (e.g. finasteride), theophylline, ethinylestradiol, terbutaline, alcohol, CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, clarithromycin, and grapefruit juice should be administered with caution as they may increase the incidence of adverse reactions. Inducers of CYP3A4 such as rifampicin, phenobarbital, phenytoin and carbamazepine may decrease plasma concentrations of tadalafil and decrease efficacy. Pregnancy and breastfeeding: Avarante is not indicated for use in women. Side Effects: Adverse events observed from spontaneous reporting and clinical trials: Common (≥1/100 and <1/10): Headache, flushing, nasal congestion, dyspepsia, back pain, myalgia, pain in extremity. Uncommon (≥1/1,000 and <1/100): Hypersensitivity reactions, dizziness, blurred vision, eye pain, tinnitus, tachycardia, palpitations, hypotension, hypertension, dyspnoea, epistaxis, abdominal pain, vomiting, nausea, gastro-oesophageal reflux, rash, haematuria, prolonged erections, chest pain, peripheral oedema, fatigue. Rare (≥1/10,000 and <1/1000): Angioedema, stroke (including haemorrhagic events), syncope, transient ischaemic attacks, migraine, seizures, transient amnesia, visual field defect, swelling of eyelids, conjunctival hyperaemia, non-arteritic anterior ischemic optic neuropathy, retinal vascular occlusion, sudden hearing loss, myocardial infarction, unstable angina pectoris, ventricular arrhythmia, urticaria, Stevens-Johnson syndrome, exfoliative dermatitis, hyperhydrosis, priapism, penile haemorrhage, haematospermia, facial oedema, sudden cardiac death. RRP: 2 pack £11.99, 4 pack £21.99, 8 pack £37.99. Supply classification: P Product licence number: PLGB 46302/0243. Product licence holder: Mylan Products Ltd, Station Close, Potters Bar, Herts, EN6 1TL, UK. Document number: UK-AVT-2024-00028. Date of preparation: November 2024.
Name of product: VIAGRA CONNECT® 50 mg Film-coated Tablets Active ingredient: Sildenafil
Product licence number: PL 50622/0063 Name and address of the product licence holder: Upjohn UK Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK Supply classification: P Indications: For erectile dysfunction in adult men. Side Effects: The safety profile of VIAGRA is based on > 9,000 patients in > 70 double-blind placebo controlled clinical studies. The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and vision blurred. Adverse reactions from post marketing surveillance has been gathered covering an estimated period >10 years. Because not all adverse reactions are reported to the Marketing Authorisation Holder and included in the safety database, the frequencies of these reactions cannot be reliably determined. Very Common (≥ 1/10): Headache. Common (≥ 1/100 and <1/10): Dizziness, Visual colour distortions (Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia), Visual disturbance, Vision blurred, Flushing, Hot flush, Nasal congestion, Nausea, Dyspepsia. Uncommon (≥ 1/1,000 and <1/100): Rhinitis, Hypersensitivity; Somnolence; Hypoaesthesia, Lacrimation disorders (Dry eye, Lacrimal disorder and Lacrimation increased), Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual brightness, Conjunctivitis, Vertigo, Tinnitus, Tachycardia, Palpitations, Hypertension, Hypotension, Epistaxis, Sinus congestion, Gastro Oesophagael reflux disease, Vomiting, Abdominal pain upper, Dry mouth, Rash, Myalgia, Pain in extremity, Haematuria, Chest pain, Fatigue, Feeling hot, Heart rate increased. Rare (≥ 1/10,000 and <1/1,000): Cerebrovascular accident, Transient ischaemic attack, Seizure, Seizure recurrence, Syncope, Non-arteritic anterior ischaemic optic neuropathy (NAION), Retinal vascular occlusion, Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect, Diplopia, Visual acuity reduced, Myopia, Asthenopia, Vitreous floaters, Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye disorder, Conjunctival hyperaemia, Eye irritation, Abnormal sensation in eye, Eyelid oedema, Scleral discoloration, Deafness, Sudden cardiac death, Myocardial infarction, Ventricular arrhythmia, Atrial fibrillation, Unstable angina, Throat tightness, Nasal oedema, Nasal dryness, Hypoaesthesia oral, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN),Penile haemorrhage, Priapism, Haematospermia, Erection increased, Irritability Precautions: Erectile dysfunction can be associated with a number of contributing conditions, e.g. hypertension, diabetes mellitus, hypercholesterolaemia or cardiovascular disease. As a result, all men with erectile dysfunction should be advised to consult their doctor within 6 months for a clinical review of potential underlying conditions and risk factors associated with erectile dysfunction (ED). If symptoms of ED have not improved after taking VIAGRA CONNECT on several consecutive occasions, or if their erectile dysfunction worsens, the patient should be advised to consult their doctor. Cardiovascular risk factors: Since there is a degree of cardiac risk associated with sexual activity, the cardiovascular status of men should be considered prior to initiation of therapy. Agents for the treatment of erectile dysfunction, including sildenafil, are not recommended to be used by those men who with light or moderate physical activity, such as walking briskly for 20 minutes or climbing 2 flights of stairs, feel very breathless or experience chest pain. The following patients are considered at low cardiovascular risk from sexual activity: patients who have been successfully revascularised (e.g. via coronary artery bypass grafting, stenting, or angioplasty), patients with asymptomatic controlled hypertension, and those with mild valvular disease. These patients may be suitable for treatment but should consult a doctor before resuming sexual activity. Patients previously diagnosed with the following must be advised to consult with their doctor before resuming sexual activity: uncontrolled hypertension, moderate to severe valvular disease, left ventricular dysfunction, hypertrophic obstructive and other cardiomyopathies, or significant arrhythmias. Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure. Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (e.g., aortic stenosis), or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure. Men with these conditions must not use the product without consulting a doctor. Sildenafil potentiates the hypotensive effect of nitrates (see Contra-indications). Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of sildenafil. Most, but not all, of these patients had pre-existing cardiovascular risk factors. Many events were reported to occur during or shortly after sexual intercourse and a few were reported to occur shortly after the use of sildenafil without sexual activity. It is not possible to determine whether these events are related directly to these factors or to other factors. Priapism: Patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia), should consult a doctor before using agents for the treatment of erectile dysfunction, including sildenafil. Prolonged erections and priapism have been occasionally reported with sildenafil in post-marketing experience. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. Concomitant use with other treatments for erectile dysfunction: The safety and efficacy of combinations of sildenafil with other treatments for erectile dysfunction have not been studied. Therefore the use of such combinations is not recommended. Effects on vision: Cases of visual defects have been reported spontaneously in connection with the intake of sildenafil and other PDE5 inhibitors (see Side Effects). Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition, have been reported spontaneously and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors (see Side Effects). Patients should be advised that in the event of any sudden visual defect, they should stop taking VIAGRA CONNECT and consult a physician immediately (see Contra-indications). Concomitant use with CYP3A4 inhibitors: Pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, cimetidine). Although, no increased incidence of adverse events was observed in these patients, they should be advised to consult a doctor before taking VIAGRA CONNECT as a 25 mg tablet may be more suitable for them (see Precautions). Concomitant use with alpha-blockers: Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals (see Precautions). This is most likely to occur within 4 hours post sildenafil dosing. In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment. Thus, patients taking alpha blockers should be advised to consult their doctor before taking VIAGRA CONNECT as a 25 mg tablet may be more suitable for them. Treatment should be stopped if symptoms of postural hypotension occur, and patients should seek advice from their doctor on what to do. Effect on bleeding: Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside in vitro. There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration. Therefore the use of sildenafil is not recommended in those patients with history of bleeding disorders or active peptic ulceration, and should only be administered after consultation with a doctor. Hepatic impairment: Patients with hepatic impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Dosage and Method of use). Renal impairment: Patients with severe renal impairment (creatinine clearance <30 mL/min), must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Dosage and Method of use). Lactose: The film coating of the tablet contains lactose. VIAGRA CONNECT should not be administered to men with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per tablet. Patients on low sodium diets can be informed that this medicinal product is essentially ‘sodium-free’. Use with alcohol Drinking excessive alcohol can temporarily reduce a man’s ability to get an erection. Men should be advised not to drink large amounts of alcohol before sexual activity. Contra-indications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway, sildenafil was shown to potentiate the hypotensive effects of nitrates, and its co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form is therefore contraindicated. Co-administration of VIAGRA CONNECT with ritonavir (a highly potent P450 enzyme inhibitor) is contraindicated (see Precautions). The co-administration of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see Precautions). Agents for the treatment of erectile dysfunction, including sildenafil, should not be used by those men for whom sexual activity may be inadvisable, and these patients should be referred to their doctor. This includes patients with severe cardiovascular disorders such as a recent (6 months) acute myocardial infarction (AMI) or stroke, unstable angina or severe cardiac failure. Sildenafil should not be used in patients with severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg) and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases). This is because the safety of sildenafil has not been studied in these sub-groups of patients, and its use is therefore contraindicated. Sildenafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure. VIAGRA CONNECT should not be used in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease). VIAGRA CONNECT is not indicated for use by women. The product is not intended for men without erectile dysfunction. This product is not intended for men under 18 years of age. Dosage and Method of use: For Oral Use: Adults: The recommended dose is one 50 mg tablet taken with water approximately one hour before sexual activity. The maximum recommended dosing frequency is once per day. If VIAGRA CONNECT is taken with food, the onset of activity may be delayed compared to the fasted state. Patients should be advised that they may need to take VIAGRA CONNECT a number of times on different occasions (a maximum of one 50 mg tablet per day), before they can achieve a penile erection satisfactory for sexual activity. If after several attempts on different dosing occasions patients are still not able to achieve a penile erection sufficient for satisfactory sexual activity, they should be advised to consult a doctor. Elderly: Dosage adjustments are not required in elderly patients (≥ 65 years old). Renal Impairment: No dosage adjustments are required for patients with mild to moderate renal impairment. However, since sildenafil clearance is reduced in individuals with severe renal impairment (creatinine clearance <30ml/min), individuals previously diagnosed with severe renal impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions). Hepatic Impairment: Sildenafil clearance is reduced in individuals with hepatic impairment (e.g. cirrhosis). Individuals previously diagnosed with mild to moderate hepatic impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions). The safety of sildenafil has not been studied in patients with severe hepatic impairment, and its use is therefore contraindicated (see Contra-indications). Paediatric population: VIAGRA CONNECT is not indicated for individuals below 18 years of age. Use in patients taking other medicinal products: Pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, erythromycin, cimetidine). With the exception of ritonavir, for which co-administration with sildenafil is contraindicated (see Contra-indications), individuals receiving concomitant treatment with CYP3A4 inhibitors must be advised to consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions). In order to minimise the potential of developing postural hypotension in patients receiving alpha blocker treatment (e.g. alfuzosin, doxazosin or tamsulosin), patients should be stabilised on alpha blocker therapy prior to initiating sildenafil treatment. Thus, patients taking alpha blockers must be advised to consult their doctor before taking VIAGRA CONNECT since a 25 mg tablet may be more suitable for them (see Precautions). Addition of a single dose of sildenafil to sacubitril/valsartan at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of sacubitril/valsartan alone. Therefore, caution should be exercised when sildenafil is initiated in patients treated with sacubitril/valsartan. C+D Trade Price (exc VAT): 2 pack £8.82, 4 pack £16.17 and 8 pack £28.39 Date of revision: 04/2023
Please continue to report suspected adverse drug reactions with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions online via the Yellow Card Website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM), free phone line: 0800–731–6789. Adverse reactions/events should also be reported to MAH at e-mail address: pv.uk@viatris.com.
The SmPC for this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/ SPCandPILs/index.htm and from Viatris Medical Information, Building 4, Trident Place, Hatfield Business Park, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, phone no. 01707 853000 Email: info.uk@viatris.com
HEALTHY SKIN FROM INSIDE & OUTSIDE
IMMEDIATE UVA/UVB PROTECTION 48H MOISTURE
IMMEDIATE UVA/UVB PROTECTION FAST ABSORBING SUN CREAM
SUN PROTECTION
IMMEDIATE UVA/UVB PROTECTION
FAST ABSORBING SUN CREAM
IMMEDIATE UVA/UVB PROTECTION
FOR KIDS’ DELICATE SKIN COLOURED FORMULA
Our nourishing after sun products cool and moisturise the skin. HELPS INSTANTLY RELIEVE SIGNS OF SUN-STRESSED SKIN
WHAT IS THE UV INDEX?
The UV Index measures the strength of the sun’s rays. Always use Sun Protection for UV index 3 or above.
CHECK YOUR WEATHER APP TO FIND OUT MORE ABOUT UV INDEX AND WHY IT'S IMPORTANT.
SIMPLIFYING CONTINENCE CARE FOR YOU AND YOUR CUSTOMERS
1 in 3 women experience bladder sensitivity and incontinence1, but only 27% of them are using the right protection.
Prevalence of bladder weakness in the UK.
In the UK it is estimated that between 3 and 6 million people experience some degree of urinary incontinence1. It is a condition that affects both men and women, and is also more common with increasing age.
Urinary incontinence can happen for a number of reasons and is more common than many people realise. As many as 1 in 3 women over the age of 35 and 1 in 4 men over the age of 40 experience bladder leakage2. Additionally, many women are not currently using the right protection for their needs.
Only 27% use purpose made products specifically designed to handle bladder weakness2, as many women use period products to manage their incontinence. The result is ineffective care, and a compromised quality of life.
A very relevant and growing category for pharmacies.
Bladder Weakness has a greater importance in the Pharmacy Channel due to the high level of education, advice and guidance required by the shopper/consumer. Equipping yourself with the right tools, products and merchandising for conversations on the topic will help generate greater customer satisfaction and loyalty. This document will help you capture this growth opportunity and help support your interactions with customers on the topic of continence care.
THE PRODUCTS FAMILY CAREGIVERS REALLY VALUE
Research has shown that when it comes to continence care, shoppers prefer to go to pharmacies (where they have the option to speak to a knowledgeable expert) over and above other retailers.
72% of caregiver relatives and 65% of male and female shoppers prefer to shop in pharmacies3
Understanding how customers find the right product for their needs
In the world of pharmacy, understanding and meeting the unique needs of your customers is the cornerstone of a successful business. By utilising consumer research and sales data, you can curate your product inventory to enhance customer satisfaction and foster the growth of your pharmacy.
To begin this journey, it’s imperative to understand how consumers navigate the bladder weakness product range. Customers use the key leading brands in pharmacy as a beacon of trust and typically start their product search by identifying their preferred brand, followed by product format and then absorption level. Neilsen sales data in pharmacy also reveals that TENA dominates the bladder weakness category with an impressive 87% market share4. Always Discreet holds a 6% share of retail sales, while various smaller brands collectively constitute the remaining 7% of sales.
Delving deeper into the Bladder Weakness category, we see the majority of sales revenue, over half in fact, stems from the Pants format. This reflects a higher level of trust consumers place in healthcare professionals when dealing with more severe incontinence conditions. To be precise,
57% of incontinence sales are attributed to Pants, followed by 28% from pads, and a just 4% from Liners4. Moreover, the Men’s category shows strong potential for growth within the pharmacy sector, boasting a remarkable growth rate of over 10% year on year4.
In light of this, it is essential to mirror this consumer preference in your fixture layout, aligning products with their respective subcategories. This strategy ensures your pharmacy is well-equipped to meet the needs of your customers effectively.
57% of incontinence sales come from pants 28% of sales come from pads just 4% come from liners
ARE YOU MAXIMISING YOUR INCONTINENCE SPACE?
HOW TO DISPLAY YOUR PRODUCT RANGE TO MAXIMISE SALES
Your stock can be the most important financial asset to your business and implementing effective merchandising can deliver significant improvements to sales performance.
We want to help you provide an easy shopping layout for your customers, to ensure they can navigate your product display and find the right product for their needs.
We have created an easy-to-follow planogram that you can implement in your pharmacy, aligning product format and space to reflect their sales potential, as well as showing adjacent sub ranges for trade up opportunities. You can see this in the below example.
OUR STEP-BY-STEP GUIDE
We’ll guide you through converstions around incontinence based on our knowledge of the topic and TENA’s understanding of the different audiences who are in need of incontinence products. This conversation guide will follow four stages helping you effectively recommend TENA products to your shoppers based on their needs.
Our shoppers
Our 4 stage process
1. Identify shoppers in need of help
2.
Reassure them that they’re not alone and there are products for their needs
3.
Establish what lifestyle they are buying products for 4. Recommend
Men buying for themselves
Women buying for themselves
Family carers buying for their loved ones
1. Identify shoppers in need of help.
Whether shoppers are standing by the incontinence shelf, or actively approaching you for support, you can encourage a dialogue by asking a few simple questions.
Once you’ve established their answers to these initial questions, you’ll be well placed to follow either of the following guides for Men, Women or Family Carers.
“Do you need help with what you’re looking for today?”
“Incontinence can be a daunting topic for many people - if it’s helpful, I can tell you what I know and we can work out which products might be able to help… There are also leaflets on the shelf that you can read in your own time, if you’d rather”
“Are you buying the product for yourself or someone else?”
2.
Reassure them that they’re not alone and there are products for their needs.
FAMILY CARERS
“You are not alone. 1 in 5 people globally are family carers.”
“Incontinence-related issues are very common amongst carees as well, as 1 in 3 women over 35 and 1 in 4 men over 40 suffer from bladder leakages.”
3.
Take the taboo out of incontinence and make your shoppers feel more comfortable talking to you, nuturing more loyal customers for your pharmacy.
MEN
“It’s much more common than you think – 1 in 4 men over the age of 40 experience drips and dribbles. If this is something you need support with, then there are plenty of good TENA products for you use.”
WOMEN
“You are not alone - as many as 1 in 3 women over the age of 35 have experienced bladder leaks.”
“It’s very common for women to experience bladder leaks at particular moments throughout life, such as pregnancy, post-partum and during the menopausal years.”
Establish what lifestyle they are buying products for. Before recommending the right product, it’s important to learn about the level of leaks of your shoppers, as well as when, where and what the product is needed for.
Level of leaks
Lifestyle
When do leaks occur
FAMILY CARERS, MEN, AND WOMEN
What level of leakage do they/you experience (describe the amount – a few drops, or something more)?
FAMILY CARERS
Which of their activities do they need protection for (e.g. out and about vs. at home vs. travelling) How would you describe their level of mobility? Are they dependent on others to change them?
MEN AND WOMEN
Describe a typical day for you (e.g. exercise, eating and drinking habits, bowel habits) Which of your activities do you most need protection for (e.g. out and about vs. at home vs. travelling)
FAMILY CARERS
When do their leakages generally happen? (i.e. Day or night?) Does this vary? Is it a rush to get them to the toilet in time or frequent toilet visits (day time or night time)?
MEN AND WOMEN
When do your leakages generally happen? Day or night? Does this vary? Are leaks more likely to happen where you’re exerting yourself - like when you cough, or sneeze, laugh, or do certain physical activity like lifting weights or running?
Is it a rush to get to the toilet in time or frequent toilet visits (day time or night time)?
4. Recommend.
Based on your shoppers’ needs, there are several resources that allow you to recommend the right product. TENA droplet sytemDifferent products for day and night Skin health products
KNOWLEDGE EQUALS CONFIDENCE
HERE ARE SOME ADDITIONAL TIPS TO DRIVE CUSTOMER LOYALTY
SIMPLIFYING THE SHOPPING EXPERIENCE
• Make products easy to find in the store and consider displaying products alongside other products that can benefit their situation (e.g. moisturizers or creams for improved skin health).
• Run in-store campaigns to improve product visibility and category awareness.
WIDER HEALTH TIPS RELATING TO URINE LEAKAGE
• Be observant of medical conditions that can cause urinary symptoms: diabetes, stroke, Parkinson’s disease and Multiple Sclerosis are a few examples. Always refer them to a healthcare professional to get a proper diagnosis and information on how to manage and treat the issue.
• Caffeine and alcohol reduction have a range of additional benefits, beyond helping reduce the occurrence of leaks.
• Remember to recommend drinking enough water – dehydration concentrates urine, which can promote an overactive bladder.
• Avoid drinking two hours before bedtime to help minimize night-time urination.
• Maintaining a healthy body weight and exercising regularly can help improve bladder health, as they encourage regular bowel movements, and help manage stress levels and psychological well-being.
• Some medications can also cause side effects that affect the bladder and bowel, so understanding what medication the shopper is on is also important.
WIDER SKIN HEALTH TIPS
• Keeping the skin clean prevents irritations – for sensitive skin you can use barrier creams for protection.
1. Where accounts have been approved for credit, payments are due 30 days from the month of invoice. Sigma Pharmaceuticals Plc reserves the right to charge interest on overdue accounts at the rate of 4% above the LIBOR (London InterBank Offered Rate) per month without prejudice to the right of recovery. Cheques payable to Sigma Pharmaceuticals Plc. Sigma Pharmaceuticals Plc reserves the right not to process the orders in case of an overdue account.
2. All orders and prices quoted are subject to the standard rate or reduced rate of V.A.T. on the NETT invoice value. The invoice date is the tax point for V.A.T. purposes.
3. Products on offer in the PLOF are not eligible for any further discounts.
4. All delivery enquiries must be notified within 24 hours of delivery
5. Prices are correct at time of going to print, but are subject to change without prior notice. Sigma Pharmaceuticals Plc reserves the right to amend any of their prices without due notice. Orders are accepted on condition that the goods will be invoiced at the prices ruling at the date of delivery. All images shown are for illustrative purposes only.
6. Invoice queries must be raised within one week of invoice date.
7. The goods shall remain the sole and absolute property of the seller and legal equitable owner until such time as the buyer shall have paid to the seller the agreed price together with the full price of any other contract with the seller.
8. Standard terms and conditions apply, as per trading terms, available upon request.
9. RSP’s shown are supplied by the manufacturers and are correct at time of going to print. It is at the retailers discretion to set their own retail price and margin.
Claims and Returns
DELIVERIES
When accepting your delivery please ensure the number of boxes/bulk received match the drivers runsheet and that any discrepancies are clearly marked. Non-delivery must be notified to Sigma Pharmaceuticals Plc within 1 service day of invoice date or advice of despatch.
RETURNS
Under existing rules and regulations issued by the DHSS and as published in “MAIL”, goods will only be accepted for return by Sigma Pharmaceuticals Plc for the following reasons:
• To correct an error in delivery or ordering.
• In response to a product or batch recall instigated by a manufacturer.
• Where products or packages are alleged to be faulty.
In order to be considered for credit or replacement the goods must be accompanied by a note showing:-
• The name and address of the customer returning the goods.
• The quantity and description of the goods.
• The invoice number on which the goods were supplied.
• The reason of the return.
Transfer Order Queries
Call 01923 331 411 and ask for the Transfer Order Department.
Expiry Date Queries
Dates on products should be checked upon delivery. If you wish to return an item due to the date, please follow the return procedure mentioned previously.
Items Missing From Delivery
Call 01923 444 999 within 24 hours of delivery.
Wrong Item Supplied
Mark the required item with the code of ‘B’ on your invoice/return slip.
Goods Ordered in Error
Mark the item with the code of ‘H’ on your invoice/return slip.
Goods Arrived Damaged
Mark the item with the code of ‘F’ on your invoice/return slip.
Recall Stock
All recall stock must be written on a return slip with the date, quantity and reason code K.
OTC & HEALTH AND BEAUTY TRANSFER ORDER OVERVIEW
Sigma offers a comprehensive transfer order service offering prompt deliveries, transparent invoicing and full advantage of manufacturers multi-level discounts (MLD) across a wide range of manufacturers.
WHY USE SICMA FOR TRANSFER ORDERS?
Our transparent invoice structure, quick turnaround and dedicated customer service means we are the preferred choice with manufacturers and third-party sales teams for transfer orders. Advantages of putting your transfer orders through Sigma:
> A minimum of 10% wholesaler discount on transfer orders)(-.
> Transparent discount structure
> More than 95% of products are available to order in singles
> Aim to deliver stock within 48 hours from receipt
> Back orders held for 60 days
> Dedicated transfer order team that can be directly contacted by telephone or email.
> Committed to ensure transfer order queries are resolved within 72 hours "Ethical and Rx Lines may not qualify for this discount
TRANSFER ORDER PORTFOLIO
BAYER
BIOKULT
•Alka Seltzer
• Protexin
• Bepanthen
• Berocca
• Mum
CLAXO SMITH l{LINE
CIGA HEALTHCARE
• Odoreaters
·ORS
HALEON
• Otex
LASER HEALTHCARE
· Alli
Allevia
•Aquafresh
Buscopan
• Beechams
BR PHARMACEUTICALS
• Canesfresh
• Canesten
• Valupak
• Clarityn
• Diprobase
CEUTA HEALTHCARE
•Feminax
• 4 Head
•Germolene
• Aloclair
• Germoloids
• Anbesol
• Redoxon
• Ashton & Parsons
• Rennie
• Astral
• Sanatogen
• Belladonna
• Blistex
BE T TERYOU
• Bloateze
• Bodyform
BIOl{ULT
• Breathe Right
• Protexin
• Carnation
• Chewy Vites
BR PHARMACEU TICALS
• Chloralieve
• Valupak
• GoldenEye
• Hydromol
• Ibuleve
CARE FOR YOURSELF LTD
• Lypsyl
• Macushield
• Milton
CEU TA HEALTHCARE
• MolluDab
• 4head
• Murine
•Alliance Pharma
• Odor - Eaters
• ORS
• Bayer
• Bazuka
• Otex
•Chloralieve
• Pepto Bismol
• Blistex
• Seven Seas
• Tena
• Bodyform
•Pepto Bismol
Aquafresh
Beechams
• Fastaid
Biotene
• Tena
Breathe Right
•Ultra Chloraseptic
• Vapodrops
Corsodyl
Nurses
• Viagra Connect
• Vicks
Driclor
• Westlab
Enos
Eumovate
Lamisil
CHURCH AND DWICHT
Nicotinell
•Anusol
Otrivine
•Arm & Hammer
Panadol
• Batiste
Piriton
• Femfresh
Poligrip
Sensodyne
•First Response
• Nair
Voltarol
Zovirax
• Orajel
• Pearl Drops
• Replens
• Sterimar
•AMO CICA HEALTHCARE
ETHICOE
• Balance Activ
•Glucogel
·Lift
•Nelsons
•Diffiam
·CBl2
•Clearblue CR LANE
• ThermaCare
• Carnation
• Ultra Chloraseptic
• Uvistat
• Flexiseq
• Freederm
• Vamousse
•lbuleve
• Viagra Connect
•Aquaban
• Derbac
• Earex
• l<alms
• Vicks
· lglu
• Milton
• Vicks Vapodrops
• Murine
• Wisdom
•Jakemans
· Olbas
•Pro Plus
• Teangi Tea Tree
Cialis Together
• Biotene
• Breathe Right
Dulco Range
• Corsodyl
Maalox
•Day Nurse
Nasacort
Opticrom
• Driclor
Pharmaton
• Duofilm
• Enos
Phenergan
Clearblue
• Eumovate
Fixodent
• Lamisil
• Nicotinell
Deep Freeze / Heat / Relief
• Otrivine
Mentholatum Ibuprofen
• Panadol
Mentholatum Vapour Rub
• Piriton
Elastoplast
Eucerin
• Poligrip
Nivea
• Polytar
Ulipristal
• Scopoderm
Just For Men
• Sensodyne
• Voltarol
Vagisil
Anthisan
• Zovirax
Cepton
Dalvit
l{ARIUM LTD
Dentinox
Dioralyte
•Cuticura
• Perspirex
Snufflebabe
Syndol
LASER HEALTHCARE
Difflam
Ricola
•Anthisan
Dextro
• Brolene
Fisherman’s Friend
• Buscopan
Bazuka
• Beiersdorf
Doublebase
• Bazuka
Freederm
•Compeed
• Dextro
Iglu
•Deep Heat/ Deep Freeze
• Dioralyte
• Dulcolax
• EllaOne
•Just For Men
•Fishermans Friend
· Nitty Gritty
PERRIGO (Omega Pharma)
Abidec
Beconase
Bio-Oil
Bronchostop
Dentu Crème
Lyclear
Milk Of Magnesia
NiQuitin
Nytol
Solpadeine
Tiger Balm
Wartner
POWERMED
PLUS
Anusol
Arm & Hammer
Batiste
Femfresh
First Response
Karium
Lotil
Nair
Orajel
Pearl Drops
Replens
Salonpas
Sterimar
RECKITT BENCKISER
Bonjela
Cuprofen
Dettol
Disprin
Durex
Full Marks
Fybogel
Gaviscon
Guardium
Lanacane
Lemsip
Nurofen
Optrex
Paramol
Senokot
Steradent
Strepsil
Sweetex
Veet
Woodwards
THE MILES GROUP
A L Simpkin
Cambridge Healthcare
Colgate Palmolive
Comedic International
Alpecin
Plantur
Kobayashi
MS George
Omron
Passion For Life
Profoot
Quies
THEA PHARMACEUTICALS
Blephaclean
Hyabak
Thealoz
Otrivine
Nutrof
Monopost
THORNTON & ROSS
Acriflex
Alegesal
Care
Cetraben
Covonia
Eucryl
Eurax
Flexitol
Fultium
Hedrin
Metanium
Movelat
Mycota
Oilatum
Radian B
Savlon
Senna
Virasorb
Virasoothe
Windsetlers
Zeroderm
Email: cs@sigmaplc.com
Tel: 0800 597 4462, Option 3
Email: rushin@sigmaplc.com
Tel: 0800 597 4462, Option 3
Email: hitesh@sigmaplc.com
Sharon Walker, Customer Services Manager
Tel: 0800 358 4427
Michelle Sparrow, Business Development Manager
Email: cs@sigmaplc.com
Tel: 01923 332 790
Dipesh Vaja, Head of Sales
Email: michelle@sigmaplc.com
Tel: 0800 597 4462
The sales team supporting you at Sigma
The sales team supporting you at Sigma
Head of Sales
Email: dipesh@sigmaplc.com
Business Development
Sales Executives
Dipesh Vaja, Head of Sales
Dipesh Vaja, Head of Sales
Tel: 0800 597 4462
Michelle Sparrow, Business Development Manager
Tel: 0800 597 4462
Tel: 01923 332 790
Email: dipesh@sigmaplc.com
Email: dipesh@sigmaplc.com
Service
Pankaj Vyas - National Sales Manager
Head of Sales
Head of Sales
Email: michelle@sigmaplc.com
Tel: 07946 352 462
Rushin Mehta, Telesales Manager
Vithal Adatia - Account Executive
Email: pankaj@sigmaplc.com
Tel: 0800 597 4462, Option 3
Dipesh Vaja, Head of Sales
Telesales/Customer Service
Dipesh Vaja, Head of Sales
Sales Executives
Tel: 0800 597 4462
Tel: 0800 597 4462
Email: rushin@sigmaplc.com
Tel: 01923 331 407
Hitesh Haria, Telesales Supervisor
Email: vithal@sigmaplc.com
Tel: 0800 597 4462, Option 3
Email: hitesh@sigmaplc.com
Email: dipesh@sigmaplc.com
Email: dipesh@sigmaplc.com
Rushin Mehta, Telesales Manager
Rushin Mehta, Telesales Manager
Tel: 0800 597 4462, Option 3
Pankaj Vyas - National Sales Manager
Tel: 07946 352 462
Tel: 0800 597 4462, Option 3
Sharon Walker, Customer Services Manager
Email: rushin@sigmaplc.com
Tel: 0800 358 4427
Hinal Pandya, Specials Manager
Email: rushin@sigmaplc.com
Email: pankaj@sigmaplc.com
Tel: 0800 597 4475
Email: cs@sigmaplc.com
Telesales/Customer Service
Telesales/Customer Service
Email: specials@sigmaplc.com
Hitesh Haria, Telesales Supervisor
Hitesh Haria, Telesales Supervisor
Tel: 0800 597 4462, Option 3
Vithal Adatia - Account Executive
Tel: 0800 597 4462, Option 3
Email: hitesh@sigmaplc.com
Tel: 01923 331 407
Email: hitesh@sigmaplc.com
Email: vithal@sigmaplc.com
Sharon Walker, Customer Services Manager
Rushin Mehta, Telesales Manager
Tel: 0800 358 4427
Rushin Mehta, Telesales Manager
Sharon Walker, Customer Services Manager
Tel: 0800 358 4427
Tel: 0800 597 4462, Option 3
Business Development Team
Email: cs@sigmaplc.com
Tel: 0800 597 4462, Option 3
OTC Transfer Orders
Email: cs@sigmaplc.com
Email: rushin@sigmaplc.com
Email: rushin@sigmaplc.com
Hinal Pandya, Specials Manager
Tel: 0800 597 4475
Michelle Sparrow, Business Development Manager
Simone Elkerton OTC Transfer Orders
Tel: 01923 332 790
Business Development Team
Email: specials@sigmaplc.com
Hitesh Haria, Telesales Supervisor
Hitesh Haria, Telesales Supervisor
Tel: 0800 597 4462, Option 3
Tel: 0800 597 4462, Option 3
Email: hitesh@sigmaplc.com
Email: hitesh@sigmaplc.com
Lisa Farrant OTC Transfer Orders
Business Development
Tel: 01923 331 411
Email: michelle@sigmaplc.com
Sharon Walker, Customer Services Manager
Sharon Walker, Customer Services Manager
Tel: 01923 331 411
Email: sim@sigmaplc.com
Tel: 0800 358 4427
Tel: 0800 358 4427
Michelle Sparrow, Business Development Manager
Email: cs@sigmaplc.com
Email: cs@sigmaplc.com
OTC Transfer Orders
Michelle Sparrow, Business Development Manager
Tel: 01923 332 790
Sales Executives
Tel: 01923 332 790
Email: michelle@sigmaplc.com
Email: lisa@sigmaplc.com
Email: michelle@sigmaplc.com
Simone Elkerton OTC Transfer Orders
Business Development
Business Development
Tel: 01923 331 411
Pankaj Vyas - North London up to Midlands
Sales Executives
Tel: 07946 352 462
Email: sim@sigmaplc.com
Lizzie Harbidge Business Development Manager
Lizzie Harbidge Business Development Manager
Email: pankaj@sigmaplc.com
Tel: 07714 657 806
Tel: 07714 657 806
Lisa Farrant OTC Transfer Orders
Reshma Patel - North East & South London
Tel: 01923 331 411
Tel: 07767 163 171
Email: lisa@sigmaplc.com
Email: reshma@sigmaplc.com
Pankaj Vyas - North London up to Midlands
Email: lizzie.h@sigmaplc.com
Email: lizzie.h@sigmaplc.com
Tel: 07946 352 462
Pankaj Vyas - National Sales Manager
Tel: 07946 352 462
Email: pankaj@sigmaplc.com
Email: pankaj@sigmaplc.com
Sales Executives
Sales Executives
Hinal Pandya, Specials Manager
Reshma Patel - North East & South London
Vithal Adatia - Account Executive
Tel: 07767 163 171
Tel: 0800 597 4475
Business Development
Tel: 01923 331 407
Email: reshma@sigmaplc.com
Email: vithal@sigmaplc.com
Email: specials@sigmaplc.com
Pankaj Vyas - National Sales Manager
Pankaj Vyas - National Sales Manager
Tel: 01923 444 999
Tel: 07946 352 462
Tel: 07946 352 462
Specials OTC Transfer Orders
Hinal Pandya, Specials Manager
Email: bd@sigmaplc.com
Specials
Specials
Hinal Pandya, Specials Manager
Email: pankaj@sigmaplc.com
Tel: 0800 597 4475
Email: pankaj@sigmaplc.com
Tel: 0800 597 4475
Email: specials@sigmaplc.com
Email: specials@sigmaplc.com
Simone Elkerton OTC Transfer Orders
Tel: 01923 331 411
OTC Transfer Orders
Email: sim@sigmaplc.com
Hinal Pandya, Specials Manager
Hinal Pandya, Specials Manager
Tel: 0800 597 4475
Tel: 0800 597 4475
Simone Elkerton OTC Transfer Orders
Vithal Adatia - Account Executive
Vithal Adatia - Account Executive
Tel: 01923 331 407
Tel: 01923 331 407
Email: vithal@sigmaplc.com
Email: vithal@sigmaplc.com
Lisa Farrant OTC Transfer Orders
Tel: 01923 331 411
Email: lisa@sigmaplc.com
Lisa Farrant OTC Transfer Orders
Email: specials@sigmaplc.com
Email: specials@sigmaplc.com
Tel: 01923 331 411
Simone Elkerton OTC Transfer Orders
Tel: 01923 331 411
Email: sim@sigmaplc.com
Email: sim@sigmaplc.com
OTC Transfer Orders
OTC Transfer Orders
Lisa Farrant OTC Transfer Orders
Tel: 01923 331 411
Tel: 01923 331 411
Email: lisa@sigmaplc.com
Email: lisa@sigmaplc.com
Simone Elkerton OTC Transfer Orders
Simone Elkerton OTC Transfer Orders
Tel: 01923 331 411
Tel: 01923 331 411
Email: sim@sigmaplc.com
Email: sim@sigmaplc.com
Lisa Farrant OTC Transfer Orders
Lisa Farrant OTC Transfer Orders
Tel: 01923 331 411
Tel: 01923 331 411
Email: lisa@sigmaplc.com
Email: lisa@sigmaplc.com
Aloclair Plus Bioadhesive
Mouth Ulcer Treatment 120ml
• Long lasting, up to 10 hours protection
• Soothes mouth ulcers and oral lesions
• For adults and children 4 years +
• Mouth wash format for those hard-to-reach areas
Aloclair Plus Bioadhesive
Mouthwash is a hands-free, hygenic treatment that easily reaches hard-to-reach areas, providing long lasting protection and helps relieve pain for people suffering from multiple mouth ulcers.
Aloclair Plus Bioadhesive Mouth Ulcer Spray 15ml
• Long lasting, up to 10 hours protection
• Helps relieve pain from mouth ulcers and oral lesions
• Targeted spray application
• For adults and children 4 years +
Aloclair Plus Bioadhesive Spray has a spray nozzle for a hygenic, handsfree application for mouth ulcers and difficult to reach lesions.
Aloclair Plus Bioadhesive Gel 8ml
• Long lasting, up to 12 hours protection
• Helps relieve pain from mouth ulcers and oral lesions
• Hygienic, targeted no-touch application
• For adults and children 4 years +
Aloclair Plus Bioadhesive Gel has a long nozzle that provides a touch free application to target visible lesions and preventing the need to use fingers to apply gel.
Provides soothing relief from troublesome teething pain where non-medicinal methods have not provided relief
Can also be used to treat mouth ulcers and denture irritation
Can be used in babies and adults from 5 months old
Anbesol Adult Strength Gel (lidocaine hydrochloride 2.0% w/w, chlorocresol 0.1% w/w, cetylpyridnium chloride 0.02% w/w). Indication: For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation. Not for use in children under 12 years. Legal Classification: GSL. Marketing Authorisation Holder: Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, UK. Information about these products, including adverse reactions, precautions, contraindications and method of use can be found at https://www.medicines.org.uk/emc/product/1304/smpc
Anbesol Teething Gel (lidocaine hydrochloride 1.0% w/w, chlorocresol 0.1% w/w, cetylpyridnium chloride 0.02% w/w). Indication: Adults, the elderly and children (from 5 months of age): For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation. In children from 5 months: For relief of pain and discomfort associated with teething where non-pharmacological treatments have failed to provide sufficient relief. For short-term use of no more than 7 days. Legal Classification: P. Marketing Authorisation Holder: Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, UK. Information about these products, including adverse reactions, precautions, contraindications and method of use can be found at https://www.medicines.org.uk/emc/product/1306/smpc
Anbesol Liquid (lidocaine hydrochloride 0.9% w/w, chlorocresol 0.1% w/w, cetylpyridnium chloride 0.02% w/w. Indication: Adults, the elderly and children (from 5 months of age): For the temporary relief of pain caused by recurrent mouth ulcers, denture irritation. In children from 5 months: For relief of pain and discomfort associated with teething where non-pharmacological treatments have failed to provide sufficient relief. For shortterm use of no more than 7 days. Legal Classification: P. Marketing Authorisation Holder:
method of use can be found at https://www.medicines.org.uk/emc/product/1305/smpc February 2025 JB-003450
HELP DITC H TH E
Anthisan Bite and Sting 2% w/w Cream Product Information
Presentation: Cream containing 2% w/w mepyramine maleate. Indications: Symptomatic relief of skin irritation caused by insect stings, insect bites and nettle stings. Dose and administration: Route of administration: Topical. Adults, elderly and children over 2 years of age and older. Anthisan Bite and Sting Cream should be applied directly to the a ected parts two or three times a day for up to three days. Contraindications: Hypersensitivity to the active substance or to any of the excipients.
Anthisan Bite and Sting Cream should not be used in eczematous conditions or on extensively broken skin surfaces, or if the skin is cut or grazed. Do not use on large areas of skin or on areas of sunburnt skin. Warnings and precautions: Repeated application of Anthisan Bite and Sting Cream to the same area for longer than three days is not recommended and treatment should be discontinued immediately if skin sensitisation occurs. Pregnancy and lactation: Anthisan Bite and Sting Cream should not be used during pregnancy or lactation, unless considered essential. Side e ects: Skin sensitisation has been reported on rare occasions. Legal category: GSL Product Licence Number: PL 35104/0038
Product licence holder: Phoenix Labs, Suite 12, Bunkilla Plaza, Bracetown Business Park, Clonee, Co. Meath, Ireland. Further information is available from Phoenix Labs, Suite 12, Bunkilla Plaza, Bracetown Business Park, Clonee, Co. Meath, Ireland. Tel +353 1 5742410, email: medicalinformation@phoenixlabs.ie. Date of preparation: January 2024
*Based on sales data. For UK contact and email verification medicalinformation@phoenixlabs.ie
**Survey of 2,000 UK bite or sting su erers, carried out by 3GEM research on behalf of Anthisan Bite and Sting Cream (July 2018)
ALL THE YOU NEED RELIEF HAYFEVER
DEFENCE RELIEF
Beconase Hayfever Relief for Adults 0.05% Nasal Spray (GSL) contains beclometasone dipropionate. For the treatment of seasonal allergic rhinitis (hayfever) in adults over 18 years. Adults aged 18 and over: 2 sprays into each nostril morning and evening (400 micrograms/day). Not recommended for use in children and adolescents under 18 years. Contraindications: Known hypersensitivity to ingredients. Caution: Concomitant use of other corticosteroid treatments, recent nasal injury or surgery, pregnancy/lactation. Side effects: Rare cases of hypersensitivity reactions, dryness/irritation of the nose and throat, raised intra-ocular pressure, nasal septal perforation. PL 02855/0065. MAH: Omega Pharma Ltd, Wrafton, Braunton, Devon, EX33 2DL, UK. RRP (ex. VAT): £7.99. Date of preparation: November 2022. SPC: https://mhraproducts4853.blob.core.windows.net/docs/1da61835df24c8494546ae270facd2fa53287d0f. BecoDefence is a medical device. Contraindications: Known hypersensitivity to ingredients or those with a Sesame oil allergy. MAT-7880
Bio-Oil ® Skincare Oil (Natural) 125ml P
Bio -O il ® Skincare Oil 125ml c Specialist scar and stretch markprodl.let '""' �r��\1�•�>eeol STRETCH MARKS I '"''�,��,�+·"'r�,"at' t;,��r,,d1 merka �--•1 ·g duong �SIIC'/ loo·,;s;,.,� .._, ,t·, wur.�•--= pw<,>d,;ol ' raj::l(j 'l.�1 �-- MIC � r-pr::, i� :::;:,�aro'ICeofe;ist'lQiilrt•!Y UN�N $KIN f'Qt,Jli htpeiroµ'(:,s•tt·•ap�-.c•ol un<1nr��- cor£inb:xh c,,htand n.v,-.,�,� 4(,[IJIIG&OCHYOR,lH;D:Sl(IN 1-•pss~v:ith&rd:cr•911H'l! Mid wrirli<lw �''-"''-"-' ht·�(�c;.;j'"H.; t,ooy a�:1 �tlj:sret&ll'l ·x.r,uu PUR(:ELLINOIL� C:,nt,a,mthe :)l'�_d1rc:��h�•"II
Bio-Oil ® Dry Skin Gel 100ml e
Bio-Oil
*Bodyform voted No.1 for comfort by 69%, and No.1 for protection by 66%, of those surveyed compared with other brands they had previously tried. In-home trial with 325 women aged 18-55, Nov23. Verify at www.bodyform.co.uk/verify. †Cour-V™ Adaptive Technology: Winner Period Care Category. Survey of 8,000 people in UK & ROI by Kantar.
Relief from symptoms caused by over 150 indoor & outdoor allergens*
Nasal Spray Ages 18+
Suitable for kids from 2+
Prescription Strength
Tablets Ages 6+
*Airborne allergens such as pets, dust, pollen and mould.
Clarityn® Allergy 10mg Tablets (loratadine). Indications: Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK (information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at https://www.medicines.org.uk/emc/ product/3506/smpc). Legal Category: GSL. Date of Preparation: March 2022.
Clarinaze® Allergy Control 0.05% nasal spray (mometasone furoate). Indications: Symptomatic treatment of seasonal or perennial allergic rhinitis in Adults aged ≥18 years. MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK. (Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at https://www.medicines.org.uk/emc/product/13697). Legal Category: P. Date of Preparation: March 2022.
Clarityn® Allergy 1mg/ml Syrup (loratadine). Indications: Symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK (information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at https://www.medicines.org.uk/emc/ product/13696/smpc). Legal Category: GSL. Date of Preparation: March 2022
® Registered trademark of Bayer AG
Feel the clarity with Clarityn
Clarityn Allergy
Syrup provides up to 24-hour allergy relief in children over the age of 2+. Sugar-free,
Non-Drowsy in 98.8% of users
The only allergy brand containing Loratadine
Suitable for ages 6+.
Relief for up to 24 hours and is non-drowsy in the majority of users.
Prescription strength relief, suitable for allergies including hayfever –without the need for a prescription.
Available behind the counter at your pharmacy.
Suitable for ages 18+.
Moderate to severe allergy sufferers may start using a few days before the allergy season.
New Cuticura Maize Body Powders
Cuticura Body Powders: NEW Maize formulation.
Available in 250g and 150g sizes.
New, easy to hold/handle plastic bottle and shaker.
NEW IMMEDIATE RESULTS FOP CLAIMS:
Tested with consumers for proven, instant results
“Instantly absorbs, softens and protects for immediate comfort and relief.
STRONGER PERFORMANCE CLAIMS:
Consumer trials on new formulation have given us stronger claims:
BOP Claims now:
85% felt their skin felt smoother after one use
94% saw reduced chafing after 2 weeks
OTHER claims:
89% of consumers trialled claimed instant results from chafing.
86% of consumers said powder cleared sweat and reduced irritation
Presentation: Powder for reconstitution with 200 ml water containing glucose 3.56 g, sodium chloride 0.47 g, potassium chloride 0.30g, disodium hydrogen citrate 0.53 g in each sachet. Indications: GSL: For the treatment of fluid and electrolyte loss associated with acute diarrhoea. P: Oral correction of fluid and electrolyte loss in infants, children and adults. Treatment of watery diarrhoea of various aetiologies including gastroenteritis in all age groups. MA holder: Phoenix Labs, Suite 12, Bunkilla Plaza, Bracetown Business Park, Clonee, Co. Meath, Ireland. Further information is available from: Phoenix Labs. Always read the label. Tel +3531 5742410, email: medical information@phoenixlabs.ie.
Legal category: Dioralyte Natural (GSL) Diora yte Blackcurrant (GSL)D oralyte Citrus (GSL), D oralyte Natural Sachets (P), D oralyte Blackcurrant Sachets (P), Dioralyte Citrus Sachets (P). Information about these products including adverse reactions, precautions, contraindications and method of use can be found at:
Presentation: Powder for reconstitution with water containing pre-cooked rice powder 6 g, sodium citrate 580 mg, sodium chloride 350 mg, potassium chloride 300 mg in each sachet. Indications: GSL: For the treatment of fluid and electrolyte loss associated with acute diarrhoea. P: Oral correction of fluid and electrolyte loss in infants aged 3 months upwards, children and adults. Treatment of watery diarrhoea of various aetiologies including gastroenteritis from 3 months upwards. Particularly recommended in the case of too loose or frequent stools where it enables over-loose stools to revert to normal.
MA holder: Phoenix Labs, Suite 12, Bunkilla Plaza, Bracetown Business Park, Clonee, Co. Meath, Ireland. Further information is available from: Phoenix Labs. Always read the label. Tel +3531 5742410, email: medical information@phoenixlabs.ie.
Dioralyte Relief Raspberry GSL. Information about these products including adverse reactions, precautions, contraindications and method of use can be found at:
Tested by dermatologists to help with dry skin conditions, E45 Bath Oil creates a lasting barrier that protects against moisture loss.
Shower Cream
Designed to help protect your skin from further drying, leaving it feeling soft and smooth.
Dry Scalp Shampoo
Dermatologically tested and specially formulated to work for both dry flaky scalps and dandruff, gently cleansing your scalp.
10 Hour Itch Relief
CLINICALLY PROVEN
Soothes itchy & irritated skin including:
PROVEN
Soothes, cools and hydrates itchy, irritated skin
Instant cooling Reduces the urge to scratch
Scan the QR code to access the pharmacy training hub or visit evanaperiods.com/hcp to learn more Reduces heavy menstrual bleeding by up to 60%1 Effective relief from period pain for up to 12 hours2
Evana® Heavy Period Relief 500 mg tablets (Tranexamic acid). Reduction of heavy menstrual bleeding over several cycles in women with regular, 21-35-day cycles with no more than 3 days variation. Ultravana® Period Pain Relief 250 mg Gastro-resistant tablets (Naproxen). For the treatment of primary dysmenorrhoea in women aged 15-50 years. Maxwellia Ltd., Alderley Park, Alderley Edge, Cheshire, SK10 4TG. Supply classification: P. Information about these products, including adverse reactions, precautions, contraindications, and method of use can be found at: evanaperiods.com/hcp/. 1. Leminen, H, & Hurskainen, R. Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety. Int J Women’s Health. 2012; 4:413–421., 2. Data on file.
CHANGING SIZE BOTTLES ARE
INSTANT DRY EYE RELIEF THAT LASTS
Treats hives from within
• For adults and children aged 12 years and over
• Available without prescription – only in pharmacies
• Lasts 24 hours
• Acts within 1 hour
• One tablet daily
• Lactose, gluten free
• 3 years shelf life
• Available in 10’s & 30’s
Product Name: Histahive 180mg Film-Coated Tablets Active ingredient: Fexofenadine Hydrochloride. Indication: indicated in relief of symptoms with chronic urticaria. Always read the label or accompanying leaflet. Legal classification: P MA Holder: Dr Reddy’s Laboratories (UK) LTD. 410
Cambridge Science Park, Milton Road, Cambridge, CB40PE Further Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: https://www.medicines.org.uk/emc/product/100389/smpc# about-medicine. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Pharmacovigilance at Dr Reddy’s via DrreddysGB@EU. Propharmagroup.com 2025-HHV-012 - Last revised 16.1.2025.
IN THE UK
Suck, chew or swallow & take with or without food
Available in two strengths, for adults and children age 4+
Fast-acting For long or short journeys Take up to 20min before travelling or at the onset of sickness You can repeat the dose after 6 hours
Kwells 300 microgram tablets. Product Authorisation Holder: Dexcel®-Pharma Ltd, 7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire, NN11 8PB, UK. Legal classification: P. Ingredients: Hyoscine Hydrobromide 300 microgram. Indications: For the prevention of travel sickness. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: www.medicines.org.uk/emc/product/11746/smpc8. Kwells Kids 150 microgram tablets. Product Authorisation Holder: Dexcel®-Pharma Ltd, 7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire, NN11 8PB, UK. Legal classification: P. Ingredients: Hyoscine Hydrobromide: 150 micrograms. Indications: For the prevention of travel sickness. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: www.medicines.org.uk/emc/product/11745/smp
https://www.medicines.org.uk/emc/product/3521
RefNo.: DRL0472 Nov23
Sinus Symptoms
Over The Counter Products
(No Prescription Required) Helps
Alleviate:
•Nasal Symptoms from Allergies & Hay Fever
•Nasal Symptoms from Cold & Flu
•Post Nasal Drip
•Sinus Pressure & Nasal Stuffiness
•Allergies from Occupational and House Dust, Fumes, Animal Dander, Grass, Pollen, Smoke, etc.
•Nasal Symptoms in CPAP Users with Sleep Apnoea
•To Loosen Thick Nasal Mucous Symptoms seen in Cystic Fibrosis and Immotile Ciliary Syndrome
Nuromol provides more effective pain relief than a prescription combination of paracetamol and codeine 1*
Nuromol gets to work faster than individual tablets of standard ibuprofen and paracetamol taken together 2–7
References: 1. Daniels SE, et al Pain. 2011;152:632–642. 2. Tanner T, et al. BMC Clin Pharmacol. 2010;10:10. 3. Wright CE, et al. Clin Pharmacol Ther. 1983;34(5):707-710. 4. Yue Y, et al. Clin Ther. 2013;35(9):1306-1320. 5. Rostami-Hodjegan A, et al. Drug Dev Ind Pharm. 2022;28(5):523-531. 6. Atkinson HC, et al. J Bioequivalence & Bioavailab. 2015;7:3. 7. Tarabar S, et al. Drugs R D. 2020;20:23-37. 8. Nuromol Pain Relief 200 mg/500 mg Film Coated Tablets. Summary of Product Characteristics. Updated June 2022. Accessed January 2023. 9. Survey of Community Pharmacists Aug-Sep 2022. 10. Mehlisch D, et al. Clin Ther. 2010;32(5):882-895. 11. Mehlisch D, et al. Clin Ther. 2010;32(6):1033-1049.
Essential Information
Nuromol Pain Relief 200 mg/500 mg film coated tablets For the temporary relief of mild to moderate pain associated with migraine, headache, backache, period pain, dental pain, rheumatic and muscular pain, pain of non-serious arthritis, cold and flu symptoms, sore throat and fever. This product is especially suitable for pain which has not been relieved by ibuprofen or paracetamol alone. Nuromol Pain Relief 200mg/500mg Film Coated Tablets is indicated in adults aged 18 years. Licence Holder: Reckitt Benckiser Healthcare (UK) Limited, Slough, SL1 3UH. Legal Classification: P. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at https://www.medicines.org.uk/emc/product/13804.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard, or search for the MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Reckitt Benckiser Healthcare (UK) ltd on: 0333 200 5345
RKT-M-09246 January 2022
TIME TO TRY SOMETHING ELSE?
If a patient has already tried paracetamol or ibuprofen but have not got the relief they needed, you now have a new GSL option available to help them get back to feeling like themself – Nuromol Dual Action Pain Relief.
What makes Nuromol Dual Action Pain Relief different to single active products?
Nuromol Dual Action Pain Relief contains interlocking paracetamol and ibuprofen, 6 which are released simultaneously to deliver a combination effect 7
Simple and convenient dosing : Take 1 tablet, if 1 tablet does not control symptoms a maximum of 2 tablets may be taken, up to 3 times a day 7
1x Nuromol Dual Action Pain Relief tablet
Provides statistically superior pain relief than a 1 g paracetamol + 30 mg codeine combination up to 12 hours 2*
THINGS TO REMEMBER
7
• Advise patients Nuromol Dual Action Pain Relief cannot be used alongside other oral or topical NSAIDs or paracetamol
• To minimise side effects, it is recommended th at patients take Nuromol Dual Action Pain Relief with food
• If patients still need pain relief after using N uromol Dual Action Pain Relief for 3 days, they should see their GP for advice
*Based on a
6s & 16s also available.
GETTING YOU THERE ONE TRY AT A TIME.
Don’t quit trying.
By combining NiQuitin Clear Patch and NiQuitin Minis Lozenges provides significant improvement in quit rate vs patch alone. To verify contact verify@perrigo.com
NiQuitin Clear 21 mg patches PL 02855/0237 GSL & NiQuitin Minis Mint 2mg Lozenges PL 02855/0328 GSL are used to relieve and/or prevent craving and nicotine withdrawal symptoms associated with nicotine dependence. Contains nicotine to aid nicotine withdrawal. Requires willpower. Always read the leaflet. MAH: Omega Pharma Ltd, Wrafton, Braunton, Devon, EX33 2DL, UK. Information about this product, including adverse reactions, precautions, contra-indications and method of use can be found at: https://mhraproducts4853.blob.core.windows.net/docs/f91bbc0fa449a4d253d88e66d31ec846b6ebf5fb. https://mhraproducts4853.blob.core.windows.net/docs/a2b169571b9c71e5e87745b08f054b757c50f6ef. Price is at the discretion of the retailer. MAT-6433
NEW EYE CATCHING LOOK
& Opticrom®
entire family symptoms within 2 minutes
1 From children aged 6 years to adults up to 65 years. Hay Fever - Opticrom Hayfever 2%w/v Eye Drops, solution 10ml. Sodium Cromoglicate. GSL. For the relief and treatment of the eye symptoms of hayfever. Aspire Pharma Ltd., Unit 4 Rotherbrook Court, Hampshire, GU32 3QG, United Kingdom. PL 35533/0031. Information about this product, including adverse reactions, precautions , contra-indications, and method of use can be found at:https://www.medicines.org.uk/emc/product/9320/smpc Allergy - Opticrom Allergy 2%w/v Eye Drops, Solution 10ml. Sodium Cromoglicate. P. For the relief and treatment of seasonal and perennial allergic conjunctivitis. Aspire Pharma Ltd., Unit 4 Rotherbrook Court, Hampshire, GU32 3QG, United Kingdom. PL 35533/0033. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at:https://www.medicines.org.uk/emc/product/9318/smpc
time use. Indications: For the treatment of acute bacterial conjunctivitis in adults and children aged 2
7-12 Tavistock Square, WC1H 9LT, UK. Information about this product, including adverse reactions, precautions, contraindications, and method of use can be found at: https://www.medicines.org. uk/emc/product/7299/smpc. All adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Reckitt Benckiser Healthcare (UK) Ltd on: 0333 200 5345. Date of preparation: November 2024. RKT-M-73534
TOOTHACHE RELIEF – STARTS IN UNDER
Symptomatic control of all allergic conditions responsive to antihistamines including:
• Hayfever and other allergies e.g., pet, house dust mite, and mould spore allergies
• Food allergies such as itchy skin, skin rash, and hives
• Also relieves the itchy rash of chickenpox
Piriton Children’s Allergy Syrup and Piriton Allergy Tablets (chlorphenamine maleate). Indications: Symptomatic relief of allergic conditions including hayfever. Symptomatic relief of itch associated with chickenpox. Legal category: P. Licence Holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK. Information about this product, including adverse reactions, precautions, contraindications and method of use can be found at: http://www.medicines.org.uk/emc/medicine/16103, https://www.medicines.org.uk/emc/product/3928/smpc
Pirilieve Relief of Chanelle Trade
POWERFUL HAYFEVER RELIEF
fexofenadine hydrochloride
Relief of symptoms associated with seasonal allergic rhinitis:
• Sneezing, a runny nose, stuffy nose, itchy nose, itchy and watery eyes, sore and scratchy throat
• Hayfever relief non-drowsy in most people
Pirilieve Hayfever Relief 120mg Film-Coated Tablets (fexofenadine hydrochloride). Indications: Relief of symptoms associated with seasonal allergic rhinitis. Legal category: GSL. Licence Holder: Chanelle Medical Unlimited Company, Dublin Road, Loughrea, Co. Galway, Ireland. Trade marks are owned by or licensed to the Haleon group of companies.
5PF034PROFOOT
Most widely prescribed proton pump inhibitor (PPI)1
Most effective PPI treatment for maintenance of GERD2
Can be used during pregnancy and whilst breast feeding
Omeprazole, the 2nd most dispensed item in England3
Care should be taken when recommending medicines for use in pregnancy as medicines can cross the placenta and may affect the fetus.
Product Authorisation Holder: Dexcel® Pharma Ltd. 7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire NN11 8PB, United Kingdom. Legal classification: GSL. Product name: Pyrocalm Control® 20mg Gastro-Resistant Tablets. Ingredients: 20 mg Omeprazole. Indications: For the short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: www.medicines.org.uk/emc/product/9154. Fertility, pregnancy and lactation: Pregnancy: results from three prospective epidemiological studies (more than 1000 exposed outcomes) indicate no adverse effects of omeprazole on pregnancy or on the health of the foetus/newborn child. Omeprazole can be used during pregnancy. Breastfeeding: Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used. Omeprazole can be used during breastfeeding. Fertility: Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility. 1NHS Digital, Practice level prescribing data 2018/19 2pubmed.ncbi.nlm.nih.gov/9692700/ 3www.statista.com/statistics/378445/ prescription-cost-analysis-top-twenty-chemicals-by-items-in-england/
Rennie® Peppermint (Calcium Carbonate 680mg and Magnesium Carbonate 80mg). Indications: For relief of indigestion and heartburn. MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK (information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at https://www. medicines.org.uk/emc/product/13863/smpc). Legal Category: GSL. Date of Preparation: March 2023. ® Registered trademark of Bayer AG. Neutralises 99% of excess stomach acid in 60 seconds
For 3 million women in UK, vaginal dryness is a real problem that affects and interferes with their day-to-day lives 1 . This is a common condition that can occur at any age:
+ OVER 50% OF WOMEN EXPERIENCE VAGINAL DRYNESS DURING THE MENOPAUSE 2
+ 17% of women aged 18-50 years also experience it during sexual intercourse 3
Yet, many women still suffer in silence. They may not know Vaginal Moisturisers exist or they still feel uncomfortable speaking about their symptoms. Subsequently, these women:
+ Won’t buy anything to help them
+ Will misdiagnose themselves with a condition such as thrush and buy the incorrect solution or product
+ Will buy only sexual lubricant as a short-term solution
THE UK’S NO.1 PRESCRIBED VAGINAL MOISTURISER*
WITH ONE APPLICATION, REPLENS TM LONG-LASTING MOISTURISER PROVIDES UP TO 3 DAYS RELIEF.
The oestrogen-free formula is clinically proven to alleviate dryness at the source. It coats the surface tissue and delivers soothing moisture and hydration to vaginal mucosa for continuous relief from:
Itching
Irritation
Discomfort
Painful intercourse
Uniquely spaced stainless steel teeth for efficient removal of lice, eggs and nits
Two row technology head lice comb
Pip Code: 416 3242 For a free sample or to order spare seals please contact us by email at: shanty@shantys.com.
Seal Code: 40025 PIP Code: 416 3259
Pip Code: 416 7946
Savlon Scar Prevention Gel
•For cuts, grazes, minor wounds & burns.
• Helps soothe pain.
Savlon Antiseptic Cream
•For minor skin problems such as cuts & grazes, spots, blackheads, nappy rash, sunburn, sores & blisters.
• A household name trusted for generations.
• Helps prevent infection.
Available in 15g, 30g, 60g & 100g.
• • Speeds up healing & reduces the likelihood of scarring.
Hydro-active colloid gel can be used on dry or wet wounds.
Savlon Burns & Scalds 0.25% w/w Cream
•For minor burns, scalds & sunburn blisters.
Savlon Antiseptic and Pain Relief Gel
•Specifically designed to treat the skin & provide effective relief.
•Helps prevent infection.
Savlon Wound Cleansing Wipes
For
• No sting & gentle on skin.
• Sterile & alcohol free.
•For painful minor wounds, scrapes, sores & shaving cuts.
•For use on broken or damaged skin such as cuts & grazes.
Biodegradable & plastic free wipes.
Travel friendly with 10 handy individual sachets.
*IRI sales data for Savlon Antiseptic Cream. To verify contact savlon@thorntonross.com Always read the label. Savlon Antiseptic Cream contains cetrimide and chlorhexidine digluconate. For the cleansing and prevention of infection in all types of lesions, ranging from minor skin disorders or blisters, to minor burns and small wounds. GSL. Thornton & Ross Ltd. Savlon Antiseptic and Pain Relief Gel / Savlon Bites & Stings Pain Relief Gel contains lidocaine hydrochloride, zinc sulphate and cetrimide. For the symptomatic relief of pain, itching, irritation, and for antiseptic protection. For use in insect bites and stings, and skin reactions such as nettle rash, caused by contact with plants. GSL. Thornton & Ross Ltd. Savlon Burns & Scalds 0.25% w/w Cream contains Chlorhexidine Gluconate. For the treatment of minor burns and scalds, scratches, cuts and abrasions, sunburn blisters and infected cracked skin. GSL. Thornton & Ross Ltd. Information about these products, including adverse reactions, precautions, contra-indications, and method of use can be found at: Savlon Antiseptic Cream: https://www.medicines.org.uk/emc/product/6330. Savlon Antiseptic and Pain Relief Gel / Savlon Bites & Stings Pain Relief Gel: https://www.medicines.org.uk/emc/product/6332. Savlon Burns & Scalds 0.25% w/w Cream: https://www.medicines.org.uk/emc/product/14486.
MAX STRENGTH PARACETAMOL
*1 tablet = 1 dose (take only one tablet at a time) **Based on absorption data
SolpaOne® 1000mg Effervescent Tablets (P) contain paracetamol. For short term symptomatic treatment of mild to moderate pain and/or fever. For adults and adolescents over 50kg of body weight aged 16 years and above. 1 tablet = 1 dose (take only one tablet at a time). Do not take more than 4 tablets (4000mg) per day. Do not use for more than 3 days unless on medical advice. Maximum paracetamol strength in 1 tablet. MAH: Cipla (EU) Limited Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, UK. Information about this product, including adverse reactions, precautions, contraindications, and method of use can be found at: https://mhraproducts4853.blob.core.windows.net/docs/0fa5f0aaeab6197db9e35e4f460b88b21e36e654
PRODUCTS NOW AVAILABLE
6 DAY EARLY PREGNANCY
High sensitivity Midstream pregnancy test which can detect hCG in the urine as early as 6 days prior to the expected period date.
BLOOD PRESSURE MONITOR
Simple user-friendly blood pressure monitor which can store blood pressure readings for two users. Also includes irregular heartbeat detection. Product includes batteries and one year warranty.
TWIN MIDSTREAM PREGNANCY
Rapid Midstream pregnancy test delivers results in 1-3 minutes which can detect hCG in the urine as early as 4 days prior to the expected period date.
DIABETES SCREENING
A rapid, convenient and cost-effective method for the indirect measurement of blood sugar levels to assist in the diagnosis and management of diabetes. Contains three test strips.
TWIN STRIP PREGNANCY
Can be carried out by collecting urine and ‘dipping’ the test in the sample, over 99% accurate.
HEALTH CHECK-UP
A rapid, ten parameter, low-cost solution to evaluate a number of conditions affecting kidney, liver and heart etc. Six dipstick tests included.
URINARY TRACT INFECTION TEST
Urinary tract infections (UTIs) are common infections which affect the urinary tract, including the bladder (cystitis) urethra (urethritis) or kidneys (kidney infection). Suresign urinary tract infection test strips can aid in the detection of elevated levels of Leukocytes or Nitrites in urine, indicating inflammation or potential bacterial infection in the patient. Contains three dipstick tests.
SUPERIOR PROTECTION
WITH SURPRISING DISCRETION
The UK’s No1 Bladder Weakness Brand*
Key Product Benefits:
The entire range provides long lasting dryness.
It’s designed to be safe and kind to the skin.
Offers the protection you’d expect from a TENA product.
Dermatologically tested and perfume free
TENA discreet effectively locks in moisture for up to 12 hours offering your customers superior protection day or night. 1 in 3 women experience bladder weakness at some point in their life. Help women find the right purpose-made product for their needs and provide your customers with protection that’s trusted by millions.
Source: Bladder Weakness RSV% by Brand and Sub-Brand - Nielsen data to 05.08.23
GET MEN COMFORTABLE SPEAKING ABOUT URINE LEAKAGE
New
For dry mouth –when just water is not enough
1 in 5 suffer from dry mouth, and water is usually the standard remedy. But for many people, water only provides brief relief.
TePe’s new hydrating mouthwash and mouth gel ease the feeling of dry mouth, provides comfort, and protects teeth. We recommend the gentle, unflavoured products for those with a very dry mouth and mildly flavoured products for those with moderate problems.
TePe® Hydrating Mouthwash TePe’s mouthwash moistens the mucosa and leaves a pleasant feeling in the mouth. Not only does it help with dry mouth, but the added 0.2 % fluoride also gives that extra protection against caries.
TePe® Hydrating Mouth Gel TePe mouth gel gives immediate and long-lasting comfort*, moistens and soothes the oral mucosa and is convenient and easy to use whenever you need it – great for on-the-go.
TePe® Hydrating Spray A saliva stimulating spray that offers refreshment for people who experience dry mouth. It immediately stimulates saliva and provides a moisturised, refreshed feeling. The spray contains xylitol and fluoride to help protect against cavities. The TePe Hydrating Mouth Spray has a mild apple/peppermint flavour, is easy to use on-the-go, whenever freshness is needed.
*The duration of the comfort is individual; people with no or very little saliva usually experience a more prolonged effect.
INTERDENTAL BRUSHES ORANGE 0.45MM 6
239-8626TEPE INTERDENTAL BRUSHES PINK 0.4MM 6
249-3252TEPE INTERDENTAL BRUSHES PURPLE 1.1MM 6
20.00%£2.12 243-0098TEPE INTERDENTAL BRUSHES RED 0.5MM 6 £2.65 20.00%£2.12
Tiger Balm Red (GSL) contains camphor, menthol, cajuput oil, clove oil. Ointment for cutaneous use for the temporary relief of muscular aches and pains. To be rubbed on the affected parts of skin as necessary (usually 2 to 3 times daily). Not to be used on children under 2 years of age. Wash hands immediately after use. Do not apply to wounds, damaged or irritated skin, discontinue use if irritation develops. Avoid contact with the eyes, mucous membranes or other tender areas. Do not bandage tightly. Keep out of reach of children. If symptoms persist after two weeks, a doctor should be consulted. Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it. Contraindications: Hypersensitivity to any of the ingredients in this product. Side effects: hypersensitivity reactions. PL 02855/0234. MAH: Omega Pharma Limited, Wrafton, Braunton, Devon, EX33 2DL, UK. Revision date: 01/2025. RRP 30g £8.99, 19g £6.35.
Tiger Balm White (GSL) contains camphor, menthol, cajuput oil, clove oil. Ointment for cutaneous use for the symptomatic relief of minor muscular aches and pains. Do not use on cwhildren under 2 years. For the treatment of tension headache in adults only. To be rubbed on the affected parts of skin as necessary (usually 2 to 3 times daily). Rub the ointment onto the forehead or temples and lightly massage in a circular motion. Use a pea-sized quantity of ointment (approximately 0.5g or less), sufficient to lightly cover the affected area. Tiger Balm White Ointment should only be applied to the forehead or the temples. Wash hands immediately after use. Do not apply to wounds, damaged or irritated skin, discontinue use if irritation develops. Avoid contact with the eyes, mucous membranes or other tender areas. Do not apply to the nostrils or inhale. Do not bandage tightly. Keep out of the reach and sight of children.Muscular aches and pains: if symptoms persist after two weeks, a doctor should be consulted. Headache: if symptoms last continuously for 24 hours or recur repeatedly within the next 7 days, medical advice should be sought. Instruct patients not to smoke or go near naked flames - risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it. Contraindications: Hypersensitivity to any of the ingredients in this product. Asthma or other diseases of the respiratory tract that involve hypersensitivity of the airways. Skin disease, open wounds, inflamed or irritated skin. Side effects: hypersensitivity reactions. PL 02855/0235. MAH: Omega Pharma Limited, Wrafton, Braunton, Devon, EX33 2DL, UK. Revision date: 01/2025. RRP 30g £8.99, 19g £6.35. Tiger Balm Neck & Shoulder Rub RRP £8.99. Tiger Balm Muscle & Tension Lotion RRP £8.90. MAT-7541 FOR TENSION HEADACHES
FEXOFENADINE:
Treathay 120 mg film-coated tablets (GSL) contains fexofenadine hydrochloride. For the relief of symptoms associated with seasonal allergic rhinitis, in adults and children aged 12 and over. Adults and children 12 years and over: 1 tablet once daily taken before a meal. Not recommended for use in children under 12 years. Contraindications: Known hypersensitivity to ingredients. Caution: elderly and renally or hepatically impaired, history of or ongoing cardiovascular disease. Pregnancy and breast-feeding: avoid in pregnancy and do not use during breast-feeding unless on the advice of a doctor. Side effects: headache, drowsiness, dizziness, nausea, fatigue, hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, flushing and systemic anaphylaxis, insomnia, nervousness, sleep disorders or nightmares/excessive dreaming (paroniria), tachycardia, palpitations, diarrhoea, rash, urticaria, pruritus. PL 16028/0190 MAH: Galpharm Healthcare Ltd., Wrafton, Braunton, EX33 2DL, United Kingdom. RRP (ex. VAT): 19g £3.33. Date of preparation: 11/2023. RRP (ex. VAT): 19g £3.33. SPC: https://mhraproducts4853.blob.core.windows.net/docs/710d70496dfabc80f887d8ab58929f73826a596b. *to verify contact verify@perrigo.com.**hayfever relief. MAT-7049
active ingredient strikes pain and inflammation at its source
Product Information. Voltarol One A Day Muscle Pain Relief 140mg Medicated Plaster (diclofenac sodium). Indications: Local symptomatic short-term treatment (max. 7 days) of pain in acute strains, sprains or bruises of the extremities following blunt trauma in adolescents from 16 years of age and adults. Legal category: GSL. Licence holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY. U.K. Information about this product, including adverse reactions, precautions, contra-indications, and method of use can be found at: https://www.medicines.org.uk/emc/product/100424/smpc. Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-VOLTR-24-00186. Scan to discover more
TRANSFER ORDER PRICE TRANSPARENCY
Sigma invoices will show both manufacturer and Sigma discounts per line.
SINGLES & OUTERS
For day to day buying, all products are available with a standard Sigma discount, irrespective of ordering a single or an outer.
MONTHLY PROMOTION BOOK
Includes a retail category management information booklet & lots of product information.
Sigma have served independent community pharmacy for the last 43 years. We will continue to serve you and assist
H D Dental Ltd
23 Station Parade, Cockfosters Road, Barnet, Hertfordshire EN4 0DW
